JPH09506779A - 乳汁中における抗体の形質転換的な産生 - Google Patents
乳汁中における抗体の形質転換的な産生Info
- Publication number
- JPH09506779A JPH09506779A JP7517602A JP51760295A JPH09506779A JP H09506779 A JPH09506779 A JP H09506779A JP 7517602 A JP7517602 A JP 7517602A JP 51760295 A JP51760295 A JP 51760295A JP H09506779 A JPH09506779 A JP H09506779A
- Authority
- JP
- Japan
- Prior art keywords
- immunoglobulin
- promoter
- sequence
- dna
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004080 milk Anatomy 0.000 title claims description 38
- 235000013336 milk Nutrition 0.000 title claims description 37
- 239000008267 milk Substances 0.000 title claims description 35
- 238000004519 manufacturing process Methods 0.000 title description 15
- 108010076119 Caseins Proteins 0.000 claims abstract description 41
- 102000011632 Caseins Human genes 0.000 claims abstract description 28
- 108020004414 DNA Proteins 0.000 claims abstract description 25
- 241000283707 Capra Species 0.000 claims abstract description 15
- 235000021247 β-casein Nutrition 0.000 claims abstract description 15
- 239000002299 complementary DNA Substances 0.000 claims abstract description 13
- 108091081024 Start codon Proteins 0.000 claims abstract description 6
- 239000002773 nucleotide Substances 0.000 claims abstract description 6
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 6
- 230000014621 translational initiation Effects 0.000 claims abstract description 6
- 108060003951 Immunoglobulin Proteins 0.000 claims description 49
- 102000018358 immunoglobulin Human genes 0.000 claims description 49
- 108090000623 proteins and genes Proteins 0.000 claims description 40
- 238000000034 method Methods 0.000 claims description 28
- 241000124008 Mammalia Species 0.000 claims description 22
- 241001465754 Metazoa Species 0.000 claims description 21
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical group NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims description 14
- 235000018102 proteins Nutrition 0.000 claims description 12
- 102000004169 proteins and genes Human genes 0.000 claims description 12
- 239000005018 casein Substances 0.000 claims description 11
- 235000021240 caseins Nutrition 0.000 claims description 11
- 229920001184 polypeptide Polymers 0.000 claims description 7
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 7
- 241000283690 Bos taurus Species 0.000 claims description 6
- 210000004602 germ cell Anatomy 0.000 claims description 6
- 241000699670 Mus sp. Species 0.000 claims description 4
- 210000002919 epithelial cell Anatomy 0.000 claims description 4
- 108091027963 non-coding RNA Proteins 0.000 claims description 4
- 102000042567 non-coding RNA Human genes 0.000 claims description 4
- 230000008488 polyadenylation Effects 0.000 claims description 4
- 102000004407 Lactalbumin Human genes 0.000 claims description 3
- 108090000942 Lactalbumin Proteins 0.000 claims description 3
- 108010060630 Lactoglobulins Proteins 0.000 claims description 3
- 102000008192 Lactoglobulins Human genes 0.000 claims description 3
- 241000699666 Mus <mouse, genus> Species 0.000 claims description 3
- 241001494479 Pecora Species 0.000 claims description 3
- 108020004511 Recombinant DNA Proteins 0.000 claims description 3
- 239000005862 Whey Substances 0.000 claims description 3
- 102000007544 Whey Proteins Human genes 0.000 claims description 3
- 108010046377 Whey Proteins Proteins 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 210000001082 somatic cell Anatomy 0.000 claims description 3
- 241000282832 Camelidae Species 0.000 claims description 2
- 241000282887 Suidae Species 0.000 claims description 2
- 210000005075 mammary gland Anatomy 0.000 claims description 2
- 241000282836 Camelus dromedarius Species 0.000 claims 1
- 241000282898 Sus scrofa Species 0.000 claims 1
- 229940072221 immunoglobulins Drugs 0.000 description 15
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 14
- 238000005516 engineering process Methods 0.000 description 10
- 239000013612 plasmid Substances 0.000 description 9
- 239000012634 fragment Substances 0.000 description 8
- 239000013598 vector Substances 0.000 description 7
- 238000010367 cloning Methods 0.000 description 6
- 235000013601 eggs Nutrition 0.000 description 6
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 5
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 5
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 5
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 241000699660 Mus musculus Species 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 238000011830 transgenic mouse model Methods 0.000 description 4
- 108020004635 Complementary DNA Proteins 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 2
- 102000004594 DNA Polymerase I Human genes 0.000 description 2
- 108010017826 DNA Polymerase I Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 238000002105 Southern blotting Methods 0.000 description 2
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 2
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 210000000069 breast epithelial cell Anatomy 0.000 description 2
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229960000187 tissue plasminogen activator Drugs 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 235000011330 Armoracia rusticana Nutrition 0.000 description 1
- 240000003291 Armoracia rusticana Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 101100184147 Caenorhabditis elegans mix-1 gene Proteins 0.000 description 1
- 102100026735 Coagulation factor VIII Human genes 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 102000012605 Cystic Fibrosis Transmembrane Conductance Regulator Human genes 0.000 description 1
- 108010079245 Cystic Fibrosis Transmembrane Conductance Regulator Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 108010058683 Immobilized Proteins Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- 108010006519 Molecular Chaperones Proteins 0.000 description 1
- 102000005431 Molecular Chaperones Human genes 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108010001014 Plasminogen Activators Proteins 0.000 description 1
- 102000001938 Plasminogen Activators Human genes 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 238000011091 antibody purification Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000002458 cell surface marker Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 229960004222 factor ix Drugs 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 229940127126 plasminogen activator Drugs 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000013391 scatchard analysis Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 101150010939 tpa gene Proteins 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 235000021249 α-casein Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/04—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from milk
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3046—Stomach, Intestines
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/01—Animal expressing industrially exogenous proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/867—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody produced via recombinant dna technology
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Environmental Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Plant Pathology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Saccharide Compounds (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.形質転換哺乳動物の乳汁から異種免疫グロブリンを得る方法であって、 a)該免疫グロブリンのタンパク質−コード化配列を有するDNAであって、 その5'末端が乳腺上皮細胞における遺伝子の優先的な発現を支持するプロモー ター配列と結合されており、その3'末端がポリアデニル化部位を含む配列と結 合されているDNAを、該哺乳動物の生殖細胞へ導入する工程、および b)該哺乳動物から乳汁を得る工程 を含む方法。 2.哺乳動物がマウス、メウシ、ヒツジ、ヤギ、オウシ、ラクダおよびブタか らなる群から選択される、請求項1記載の方法。 3.プロモーターがカゼインプロモーター、ベータラクトグロブリンプロモー ター、乳清酸タンパク質プロモーター、およびラクトアルブミンプロモーターか らなる群から選択される、請求項1記載の方法。 4.免疫グロブリンが重鎖および軽鎖を含む、請求項1記載の方法。 5.免疫グロブリンが一本鎖ポリペプチドを含む、請求項1記載の方法。 6.免疫グロブリンがヒト由来である、請求項1記載の方法。 7.免疫グロブリンが哺乳動物の乳汁から精製される、請求項1記載の方法。 8.全ての生殖細胞および体細胞が、免疫グロブリン重鎖および軽鎖をコード 化する組換えDNA配列であって、5'末端が乳腺上皮細胞における遺伝子の優 先的な発現を支持するプロモーター配列と結合されており、3'末端がポリアデ ニル化部位を含む配列と結合されている配列を含んでいるヒト以外の形質転換哺 乳動物。 9.哺乳動物がマウス、メウシ、ヒツジ、ヤギ、オウシ、ラクダおよびブタか らなる群から選択される、請求項8記載の形質転換哺乳動物。 10.プロモーターがカゼインプロモーター、ベータラクトグロブリンプロモ ーター、乳清酸タンパク質プロモーター、およびラクトアルブミンプロモーター からなる群から選択される、請求項8記載の形質転換哺乳動物。 11.免疫グロブリンが重鎖および軽鎖を含む、請求項8記載の形質転換哺乳 動物。 12.免疫グロブリンが一本鎖ポリペプチドを含む、請求項8記載の形質転換 哺乳動物。 13.免疫グロブリンがヒト由来である、請求項8記載の形質転換哺乳動物。 14.5'〜3'の順に a)ベータカゼイン遺伝子由来の5'プロモーター配列 b)唯一のXhoI制限部位、および c)ヤギベータカゼイン遺伝子由来の3'未翻訳配列 を含む、単離した精製DNAであって、a)はヤギベータカゼインのヌクレオチ ド−6168〜−1を含み、ヌクレオチド1はベータカゼイン翻訳開始コドンの 最初のヌクレオチドであり、b)は配列 を含み、c)は、ベータカゼインcDNA配列のbp648にあるPpuMIで始 まり、7.1kb下部で継続し、配列 で終わる配列を含むDNA。 15.免疫グロブリンcDNAがb)に挿入されており、該DNAが形質転換 動物において免疫グロブリンの乳腺特異的発現を支配する、請求項14記載のD NA。 16.免疫グロブリンが重鎖および軽鎖を含む、請求項15記載のDNA。 17.免疫グロブリンが一本鎖ポリペプチドを含む、請求項15記載のDNA 。 18.免疫グロブリンがヒト由来である、請求項15記載のDNA。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US170,579 | 1993-12-20 | ||
US08/170,579 US5827690A (en) | 1993-12-20 | 1993-12-20 | Transgenic production of antibodies in milk |
PCT/US1994/014795 WO1995017085A1 (en) | 1993-12-20 | 1994-12-20 | Transgenic production of antibodies in milk |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006273219A Division JP2007006900A (ja) | 1993-12-20 | 2006-10-04 | 乳汁中における抗体の形質転換的な産生 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH09506779A true JPH09506779A (ja) | 1997-07-08 |
JP3970923B2 JP3970923B2 (ja) | 2007-09-05 |
Family
ID=22620446
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP51760295A Expired - Lifetime JP3970923B2 (ja) | 1993-12-20 | 1994-12-20 | 乳汁中における抗体の形質転換的な産生 |
JP2006273219A Pending JP2007006900A (ja) | 1993-12-20 | 2006-10-04 | 乳汁中における抗体の形質転換的な産生 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006273219A Pending JP2007006900A (ja) | 1993-12-20 | 2006-10-04 | 乳汁中における抗体の形質転換的な産生 |
Country Status (12)
Country | Link |
---|---|
US (3) | US5827690A (ja) |
EP (2) | EP0741515B1 (ja) |
JP (2) | JP3970923B2 (ja) |
AT (1) | ATE253817T1 (ja) |
AU (2) | AU688845B2 (ja) |
CA (1) | CA2178941C (ja) |
DE (1) | DE69433325T2 (ja) |
DK (1) | DK0741515T3 (ja) |
ES (1) | ES2210281T3 (ja) |
NZ (1) | NZ278744A (ja) |
PT (1) | PT741515E (ja) |
WO (1) | WO1995017085A1 (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009512694A (ja) * | 2005-10-21 | 2009-03-26 | ジーティーシー バイオセラピューティックス インコーポレイテッド | 抗体依存性細胞障害活性を増強させた抗体、その調製法および使用法 |
JP2014525395A (ja) * | 2011-08-10 | 2014-09-29 | ラボラトワール フランセ デュ フラクショヌマン エ デ ビオテクノロジー | 高度ガラクトシル化抗体 |
JP2017520531A (ja) * | 2014-06-02 | 2017-07-27 | ラボラトワール フランセ デュ フラクショヌマン エ デ ビオテクノロジーLaboratoire Francais du Fractionnement et des Biotechnologies | Fc断片の産生 |
US10034921B2 (en) | 2013-02-13 | 2018-07-31 | Laboratoire Français Du Fractionnement Et Des Biotechnologies | Proteins with modified glycosylation and methods of production thereof |
US10174110B2 (en) | 2013-02-13 | 2019-01-08 | Laboratoire Français Du Fractionnement Et Des Biotechnologies | Highly galactosylated anti-TNF-α antibodies and uses thereof |
Families Citing this family (547)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE122007000007I1 (de) | 1986-04-09 | 2007-05-16 | Genzyme Corp | Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern |
US6657103B1 (en) | 1990-01-12 | 2003-12-02 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6057287A (en) | 1994-01-11 | 2000-05-02 | Dyax Corp. | Kallikrein-binding "Kunitz domain" proteins and analogues thereof |
GB9406974D0 (en) | 1994-04-08 | 1994-06-01 | Pharmaceutical Proteins Ltd | Transgenic production |
EP0973934A4 (en) * | 1997-02-25 | 2003-02-05 | Genzyme Transgenics Corp | NON-SECRETED PROTEINS PRODUCED TRANSGENICALLY |
US6011197A (en) | 1997-03-06 | 2000-01-04 | Infigen, Inc. | Method of cloning bovines using reprogrammed non-embryonic bovine cells |
EP1555319A3 (en) | 1997-10-20 | 2006-03-15 | GTC Biotherapeutics, Inc. | Modified nucleic acid sequences and method to increasing mRNA levels and protein expression in cell systems |
US6118044A (en) * | 1997-11-14 | 2000-09-12 | Sankyo Company, Limited | Transgenic animal allergy models and methods for their use |
US7790856B2 (en) | 1998-04-07 | 2010-09-07 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize beta amyloid peptide |
TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
US7964192B1 (en) | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
US20080050367A1 (en) | 1998-04-07 | 2008-02-28 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
US7179892B2 (en) | 2000-12-06 | 2007-02-20 | Neuralab Limited | Humanized antibodies that recognize beta amyloid peptide |
US20030005468A1 (en) * | 1998-06-19 | 2003-01-02 | Meade Harry M. | Methods and vectors for improving nucleic acid expression |
US6962702B2 (en) | 1998-06-22 | 2005-11-08 | Immunomedics Inc. | Production and use of novel peptide-based agents for use with bi-specific antibodies |
HUP0102530A3 (en) | 1998-09-11 | 2006-02-28 | Korea Advanced Inst Sci & Tech | Mammary gland tissue-specific expression system using betha-casein promoter site of korean native goat |
US6258998B1 (en) | 1998-11-24 | 2001-07-10 | Infigen, Inc. | Method of cloning porcine animals |
US6700037B2 (en) | 1998-11-24 | 2004-03-02 | Infigen, Inc. | Method of cloning porcine animals |
EE05627B1 (et) * | 1998-12-23 | 2013-02-15 | Pfizer Inc. | CTLA-4 vastased inimese monoklonaalsed antikehad |
US7109003B2 (en) | 1998-12-23 | 2006-09-19 | Abgenix, Inc. | Methods for expressing and recovering human monoclonal antibodies to CTLA-4 |
RS51309B (sr) | 1998-12-23 | 2010-12-31 | Pfizer Inc. | Humana monoklonalna antitela za ctla-4 |
DE60037397T2 (de) | 1999-01-06 | 2008-06-05 | Merrimack Pharmaceuticals, Inc., Cambridge | Expression von ausgeschiedenem, menschlichem alpha-fetoprotein in transgenen tieren |
US7208576B2 (en) | 1999-01-06 | 2007-04-24 | Merrimack Pharmaceuticals, Inc. | Non-glycosylated human alpha-fetoprotein, methods of production, and uses thereof |
US7312318B2 (en) | 2002-03-01 | 2007-12-25 | Immunomedics, Inc. | Internalizing anti-CD74 antibodies and methods of use |
SI1488806T1 (sl) * | 1999-06-01 | 2016-02-29 | Biogen Ma Inc. | Blokirno monoklonsko protitelo proti vla-1 in njegova uporaba za zdravljenje žilnih obolenj |
UA81216C2 (en) | 1999-06-01 | 2007-12-25 | Prevention and treatment of amyloid disease | |
WO2001000855A1 (en) * | 1999-06-23 | 2001-01-04 | Ppl Therapeutics (Scotland) Ltd. | Fusion proteins incorporating lysozyme |
EP1792991A1 (en) | 1999-08-24 | 2007-06-06 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
US7605238B2 (en) * | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
US20030129745A1 (en) * | 1999-10-28 | 2003-07-10 | Robl James M. | Gynogenetic or androgenetic production of pluripotent cells and cell lines, and use thereof to produce differentiated cells and tissues |
US7820878B2 (en) * | 1999-11-19 | 2010-10-26 | Kyowa Hakko Kirin Co., Ltd. | Production of ungulates, preferably bovines that produce human immunoglobulins |
US7074983B2 (en) * | 1999-11-19 | 2006-07-11 | Kirin Beer Kabushiki Kaisha | Transgenic bovine comprising human immunoglobulin loci and producing human immunoglobulin |
US7414170B2 (en) * | 1999-11-19 | 2008-08-19 | Kirin Beer Kabushiki Kaisha | Transgenic bovines capable of human antibody production |
AU1777301A (en) * | 1999-11-19 | 2001-05-30 | Hematech, Llc | Production of ungulates, preferably bovines that produce human immunoglobulins |
NZ523220A (en) * | 2000-06-19 | 2005-03-24 | Gtc Biotherapeutics Inc | Transgenically produced platelet derived growth factor |
US7288390B2 (en) | 2000-08-07 | 2007-10-30 | Centocor, Inc. | Anti-dual integrin antibodies, compositions, methods and uses |
UA81743C2 (uk) | 2000-08-07 | 2008-02-11 | Центокор, Инк. | МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ |
US6902734B2 (en) | 2000-08-07 | 2005-06-07 | Centocor, Inc. | Anti-IL-12 antibodies and compositions thereof |
US20040226052A1 (en) * | 2000-10-13 | 2004-11-11 | Meade Harry M. | Methods of producing a target molecule in a transgenic animal and purification of the target molecule |
MXPA03004313A (es) | 2000-11-17 | 2007-02-27 | Hematech Llc | Expresion de inmunoglobulinas xenogenas (humanas) en ungulados transgenicos, clonados. |
US7700751B2 (en) | 2000-12-06 | 2010-04-20 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize β-amyloid peptide |
TWI255272B (en) | 2000-12-06 | 2006-05-21 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
AU2002231736A1 (en) | 2000-12-22 | 2002-07-08 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Use of repulsive guidance molecule (rgm) and its modulators |
US7491534B2 (en) | 2000-12-22 | 2009-02-17 | Kirin Holdings Kabushiki Kaisha | Methods for altering cell fate to generate T-cells specific for an antigen of interest |
AU2002232858B2 (en) | 2000-12-22 | 2007-01-11 | Sab, Llc | Methods for cloning mammals using reprogrammed donor chromatin or donor cells |
US20020142397A1 (en) * | 2000-12-22 | 2002-10-03 | Philippe Collas | Methods for altering cell fate |
EP1399483B1 (en) | 2001-01-05 | 2010-04-14 | Pfizer Inc. | Antibodies to insulin-like growth factor i receptor |
ES2347532T3 (es) * | 2001-04-13 | 2010-11-02 | Biogen Idec Ma Inc. | Anticuerpos contra vla-1. |
US20050107596A1 (en) * | 2001-04-23 | 2005-05-19 | Madaio Michael P. | Anti-alpha3(IV)nc1 monoclonal antibodies and animal model for human anti-glomerular basement membrane autoantibody disease |
GB0110029D0 (en) * | 2001-04-24 | 2001-06-13 | Grosveld Frank | Transgenic animal |
CA2447114A1 (en) * | 2001-05-16 | 2002-11-21 | Abgenix, Inc. | Human antipneumococcal antibodies from non-human animals |
ZA200700168B (en) | 2001-10-10 | 2010-02-24 | Novo Nordisk As | Remodeling and glycoconjugation of peptides |
EP2292271A3 (en) | 2001-10-10 | 2011-09-14 | BioGeneriX AG | Remodelling and glycoconjugation of an antibody |
AR039067A1 (es) | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
CN100374457C (zh) | 2001-11-14 | 2008-03-12 | 森托科尔公司 | 抗il-6抗体、组合物、方法和用途 |
US7230085B2 (en) * | 2001-11-28 | 2007-06-12 | Immunomedics, Inc. | Anti-DOTA antibody |
EP2990394A1 (en) | 2001-11-30 | 2016-03-02 | Biogen MA Inc. | Antibodies against monocyte chemotactic proteins |
US6578724B1 (en) * | 2001-12-29 | 2003-06-17 | United States Can Company | Connector for use in packaging aerosol containers |
WO2003062278A1 (en) | 2002-01-25 | 2003-07-31 | G2 Therapies Ltd | MONOCLONAL ANTIBODIES AGAINST EXTRACELLULAR LOOPS OF C5aR |
JP4498746B2 (ja) | 2002-02-14 | 2010-07-07 | イミューノメディクス、インコーポレイテッド | 抗cd20抗体およびその融合タンパク質ならびに使用法 |
US8287864B2 (en) * | 2002-02-14 | 2012-10-16 | Immunomedics, Inc. | Structural variants of antibodies for improved therapeutic characteristics |
AR038568A1 (es) | 2002-02-20 | 2005-01-19 | Hoffmann La Roche | Anticuerpos anti-a beta y su uso |
MXPA04008267A (es) | 2002-02-25 | 2004-11-10 | Elan Pharm Inc | Administracion de agentes para el tratamiento de la inflamacion. |
AU2003208946A1 (en) * | 2002-02-28 | 2003-09-16 | Eli Lilly And Company | Anti-interleukin-1 beta analogs |
MY139983A (en) | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
BRPI0308585B8 (pt) | 2002-03-13 | 2021-05-25 | Biogen Idec Inc | anticorpo isolado ou fragmento de ligação a antígeno do mesmo que se liga à alfavbeta6, composição, método de detecção in vitro de alfavbeta6 e construção de dna |
EP1503794B9 (en) * | 2002-04-12 | 2012-09-19 | Medarex, Inc. | Methods of treatement using ctla-4 antibodies |
CN1668187A (zh) | 2002-05-17 | 2005-09-14 | 赫马技术有限公司 | 能够产生人抗体的转基因有蹄动物 |
ATE477020T1 (de) | 2002-06-07 | 2010-08-15 | Dyax Corp | Prevention und verringerung von ischemia |
US7153829B2 (en) | 2002-06-07 | 2006-12-26 | Dyax Corp. | Kallikrein-inhibitor therapies |
US20040172667A1 (en) * | 2002-06-26 | 2004-09-02 | Cooper Richard K. | Administration of transposon-based vectors to reproductive organs |
US7527966B2 (en) * | 2002-06-26 | 2009-05-05 | Transgenrx, Inc. | Gene regulation in transgenic animals using a transposon-based vector |
WO2004002417A2 (en) | 2002-06-28 | 2004-01-08 | Centocor, Inc. | Mammalian ch1 deleted mimetibodies, compositions, methods and uses |
USRE47770E1 (en) | 2002-07-18 | 2019-12-17 | Merus N.V. | Recombinant production of mixtures of antibodies |
CN101537180B (zh) * | 2002-07-18 | 2016-02-10 | 莫鲁斯有限公司 | 抗体混合物的重组生产 |
KR101115797B1 (ko) | 2002-08-01 | 2012-07-27 | 이뮤노메딕스, 인코오포레이티드 | 알파 태아 단백질 Immu31 항체 및 융합단백질, 및이들의 이용 방법 |
JP2005537006A (ja) * | 2002-08-28 | 2005-12-08 | ダイアックス、コープ | 臓器及び組織の保存方法 |
WO2004026427A2 (en) * | 2002-09-17 | 2004-04-01 | Gtc Biotherapeutics, Inc. | Isolation of immunoglobulin molecules that lack inter-heavy chain disulfide bonds |
US7541440B2 (en) | 2002-09-30 | 2009-06-02 | Immunomedics, Inc. | Chimeric, human and humanized anti-granulocyte antibodies and methods of use |
US8506959B2 (en) | 2002-11-01 | 2013-08-13 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
TW200509968A (en) | 2002-11-01 | 2005-03-16 | Elan Pharm Inc | Prevention and treatment of synucleinopathic disease |
BR0315300A (pt) * | 2002-11-08 | 2005-08-30 | Hematech Llc | Ungulados transgênicos tendo atividade de proteìna priÈnica reduzida e seus usos |
US20040162414A1 (en) * | 2002-11-22 | 2004-08-19 | Santora Ling C. | Method for reducing or preventing modification of a polypeptide in solution |
US20040101939A1 (en) * | 2002-11-22 | 2004-05-27 | Santora Ling C. | Method for reducing or preventing modification of a polypeptide in solution |
WO2004050847A2 (en) * | 2002-11-27 | 2004-06-17 | Gtc Biotherapeutics, Inc. | Modified antibodies stably produced in milk and methods of producing same |
US7534427B2 (en) | 2002-12-31 | 2009-05-19 | Immunomedics, Inc. | Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins |
MXPA05007843A (es) | 2003-01-24 | 2005-10-18 | Elan Pharm Inc | Composicion y tratamiento de enfermedades desmielinizantes y paralisis por administracion de agentes de remielinizantes. |
SG155777A1 (en) | 2003-04-09 | 2009-10-29 | Neose Technologies Inc | Glycopegylation methods and proteins/peptides produced by the methods |
TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
TWI374893B (en) | 2003-05-30 | 2012-10-21 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
ES2408582T3 (es) | 2003-05-30 | 2013-06-21 | Merus B.V. | Biblioteca de Fab para la preparación de una mezcla de anticuerpos |
US20100069614A1 (en) | 2008-06-27 | 2010-03-18 | Merus B.V. | Antibody producing non-human mammals |
US9708410B2 (en) | 2003-05-30 | 2017-07-18 | Janssen Biotech, Inc. | Anti-tissue factor antibodies and compositions |
AU2004255557B2 (en) | 2003-06-09 | 2010-06-10 | Alnylam Pharmaceuticals, Inc. | Method of treating neurodegenerative disease |
CA2528551A1 (en) | 2003-06-13 | 2005-01-13 | Biogen Idec Ma Inc. | Aglycosyl anti-cd154 (cd40 ligand) antibodies and uses thereof |
US8038983B2 (en) * | 2003-07-29 | 2011-10-18 | Immunomedics, Inc. | Fluorinated carbohydrate conjugates |
WO2005012493A2 (en) | 2003-07-31 | 2005-02-10 | Immunomedics, Inc. | Anti-cd19 antibodies |
HN2004000285A (es) | 2003-08-04 | 2006-04-27 | Pfizer Prod Inc | ANTICUERPOS DIRIGIDOS A c-MET |
US20050221383A1 (en) | 2003-08-08 | 2005-10-06 | Choong-Chin Liew | Osteoarthritis biomarkers and uses thereof |
AU2004263538B2 (en) * | 2003-08-08 | 2009-09-17 | Immunomedics, Inc. | Bispecific antibodies for inducing apoptosis of tumor and diseased cells |
JP2007503838A (ja) * | 2003-09-05 | 2007-03-01 | ジーティーシー バイオセラピューティクス, インコーポレイティド | トランスジェニック動物の乳汁中での融合タンパク質の産生方法 |
AR045563A1 (es) * | 2003-09-10 | 2005-11-02 | Warner Lambert Co | Anticuerpos dirigidos a m-csf |
CA2540667A1 (en) | 2003-09-30 | 2005-04-14 | Sterrenbeld Biotechnologie North America, Inc. | A process for producing exogenous protein in the milk of trangenic mammals and a process for purifying proteins therefrom |
UA89481C2 (uk) | 2003-09-30 | 2010-02-10 | Центокор, Инк. | Еритропоетинові міметичні шарнірно-серцевинні міметитіла людини, композиції, способи та застосування |
WO2005062881A2 (en) | 2003-12-24 | 2005-07-14 | Transgenrx, Inc. | Gene therapy using transposon-based vectors |
NL1027975C2 (nl) * | 2004-01-09 | 2005-12-23 | Pfizer | Antilichamen tegen MAdCAM. |
DK1737971T3 (da) | 2004-01-20 | 2017-11-13 | Merus Nv | Blandinger af bindingsproteiner |
US20050186608A1 (en) * | 2004-02-19 | 2005-08-25 | Olsen Byron V. | Method for the production of transgenic proteins useful in the treatment of obesity and diabetes |
US20050197496A1 (en) * | 2004-03-04 | 2005-09-08 | Gtc Biotherapeutics, Inc. | Methods of protein fractionation using high performance tangential flow filtration |
MXPA06011425A (es) * | 2004-03-31 | 2007-03-12 | Johnson & Johnson | Memiticuerpos de peptido-1 similar a glucagon de humano, composiciones, metodos y usos. |
US7420099B2 (en) * | 2004-04-22 | 2008-09-02 | Kirin Holdings Kabushiki Kaisha | Transgenic animals and uses thereof |
WO2006003179A2 (en) | 2004-07-01 | 2006-01-12 | Novo Nordisk A/S | Antibodies binding to receptors kir2dl1, -2, 3 but not kir2ds4 and their therapeutic use |
WO2006008639A1 (en) | 2004-07-16 | 2006-01-26 | Pfizer Products Inc. | Combination treatment for non-hematologic malignancies using an anti-igf-1r antibody |
AU2005287406B2 (en) | 2004-07-26 | 2011-08-18 | Biogen Ma Inc. | Anti-CD154 antibodies |
MX2007001679A (es) | 2004-08-09 | 2007-05-23 | Elan Pharm Inc | Prevencion y tratamiento de la enfermedad sinucleinopatica y amiloidogenica. |
CA2478458A1 (en) | 2004-08-20 | 2006-02-20 | Michael Panzara | Treatment of pediatric multiple sclerosis |
US7393662B2 (en) * | 2004-09-03 | 2008-07-01 | Centocor, Inc. | Human EPO mimetic hinge core mimetibodies, compositions, methods and uses |
US7235530B2 (en) | 2004-09-27 | 2007-06-26 | Dyax Corporation | Kallikrein inhibitors and anti-thrombolytic agents and uses thereof |
AU2005291486A1 (en) * | 2004-10-01 | 2006-04-13 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Novel antibodies directed to the mammalian EAG1 ion channel protein |
CA2582194A1 (en) | 2004-10-05 | 2006-04-20 | Neuralab Limited | Methods and compositions for improving recombinant protein production |
WO2006040153A2 (en) * | 2004-10-13 | 2006-04-20 | Ablynx N.V. | Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease |
CA2587597A1 (en) | 2004-11-19 | 2006-05-26 | Biogen Idec Ma Inc. | Treatment for multiple sclerosis |
US20090169477A1 (en) * | 2004-12-03 | 2009-07-02 | Michael Panzara | Delaying or preventing onset of multiple sclerosis |
US20060121004A1 (en) * | 2004-12-07 | 2006-06-08 | Yann Echelard | Methods of reducing the incidence of rejection in tissue transplantation through the use of recombinant human antithrombin |
US20060130159A1 (en) * | 2004-12-09 | 2006-06-15 | Nick Masiello | Method of purifying recombinant MSP 1-42 derived from Plasmodium falciparum |
PE20061329A1 (es) | 2004-12-15 | 2006-12-08 | Neuralab Ltd | Anticuerpos ab humanizados para mejorar la cognicion |
CN101495498B (zh) | 2005-02-07 | 2013-09-18 | 基因信息公司 | 轻度骨关节炎生物标志物及其用途 |
US20080019905A9 (en) * | 2005-02-18 | 2008-01-24 | Strome Scott E | Method of using an anti-CD137 antibody as an agent for radioimmunotherapy or radioimmunodetection |
WO2006089095A2 (en) | 2005-02-17 | 2006-08-24 | Biogen Idec Ma Inc. | Treating neurological disorders |
CN103751780A (zh) | 2005-03-02 | 2014-04-30 | 比奥根艾迪克Ma公司 | 用于治疗th2介导的疾病的kim-1抗体 |
AU2006218454B2 (en) | 2005-03-03 | 2011-11-17 | Immunomedics, Inc. | Humanized L243 antibodies |
AR053553A1 (es) | 2005-03-08 | 2007-05-09 | Pharmacia & Upjohn Co Llc | Composicion de anticuerpos anti molecula de adhesion celular adresina mucosa (anti-madcam) |
EP3312196B1 (en) | 2005-03-23 | 2019-07-17 | Genmab A/S | Antibodies against cd38 for treatment of multiple myeloma |
EP2384767B1 (en) | 2005-03-24 | 2016-03-09 | Millennium Pharmaceuticals, Inc. | Antibodies that bind OV064 and methods of use therefor |
ES2657443T3 (es) | 2005-03-25 | 2018-03-05 | Gitr, Inc. | Anticuerpos anti-GITR y usos de los mismos |
TWI362940B (en) | 2005-03-31 | 2012-05-01 | Gen Hospital Corp | A use of agonist and/or antagonist of hgf/hgfr activity |
CN101351710B (zh) | 2005-04-04 | 2013-06-05 | 生物基因Idecma公司 | 评价对治疗性蛋白质的免疫应答的方法和产品 |
US8475794B2 (en) | 2005-04-06 | 2013-07-02 | Ibc Pharmaceuticals, Inc. | Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases |
US8349332B2 (en) | 2005-04-06 | 2013-01-08 | Ibc Pharmaceuticals, Inc. | Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases |
EA201100642A1 (ru) * | 2005-04-25 | 2011-12-30 | Пфайзер Инк. | Антитела к миостатину |
MX2007013304A (es) | 2005-04-26 | 2007-12-13 | Pfizer | Anticuerpos de p-caderina. |
PE20061324A1 (es) | 2005-04-29 | 2007-01-15 | Centocor Inc | Anticuerpos anti-il-6, composiciones, metodos y usos |
SI1879573T1 (sl) | 2005-05-10 | 2013-04-30 | Incyte Corporation Experimental Station | Modulatorji indolamin 2,3-dioksigenaze in postopki za uporabo le-te |
LT2460831T (lt) | 2005-05-27 | 2016-12-12 | Biogen Ma Inc. | Tweak rišantys antikūnai |
EP1907001B1 (en) * | 2005-06-17 | 2015-07-15 | Merck Sharp & Dohme Corp. | Ilt3 binding molecules and uses therefor |
ES2710289T3 (es) | 2005-06-30 | 2019-04-24 | Janssen Biotech Inc | Anticuerpos anti-IL-23, composiciones, procedimientos y usos |
CN102875681A (zh) | 2005-07-08 | 2013-01-16 | 拜奥根Idec马萨诸塞公司 | 抗-αvβ6抗体及其用途 |
AU2006278260B2 (en) * | 2005-08-08 | 2012-03-08 | Onconon, Llc. | Antibody compositions, methods for treating neoplastic disease and methods for regulating fertility |
MY164457A (en) | 2005-09-07 | 2017-12-15 | Amgen Fremont Inc | Human monoclonal antibodies to activin receptor-like kinase-1 |
ES2542501T3 (es) | 2005-09-30 | 2015-08-06 | Abbvie Deutschland Gmbh & Co Kg | Dominios de unión de proteínas de la familia de proteínas de moléculas de orientación repulsiva (RGM) y fragmentos funcionales de las mismas, así como su uso |
TW200730825A (en) | 2005-10-21 | 2007-08-16 | Genenews Inc | Method and apparatus for correlating levels of biomarker products with disease |
AU2012201010B2 (en) * | 2005-10-21 | 2015-01-22 | Genzyme Corporation | Antibodies with enhanced antibody-dependent cellular cytoxicity activity, methods of their production and use |
EP1954311A4 (en) | 2005-12-07 | 2009-12-23 | Medarex Inc | CTLA-4 ANTIBODY DOSAGE ESCALATION THERAPY |
US9181344B2 (en) | 2005-12-15 | 2015-11-10 | Genmab A/S | Use of effector-function-deficient antibodies for treatment of auto-immune diseases |
RS60616B1 (sr) | 2005-12-29 | 2020-09-30 | Janssen Biotech Inc | Humana anti-il-23 antitela, kompozicije, postupci i upotrebe |
ES2396440T3 (es) | 2006-01-18 | 2013-02-21 | The General Hospital Corporation | Métodos de aumentar la función linfática |
US7531632B2 (en) * | 2006-02-16 | 2009-05-12 | Gtc Biotherapeutics, Inc. | Clarification of transgenic milk using depth filtration |
WO2007103814A2 (en) | 2006-03-03 | 2007-09-13 | University Of Southern California | Angiogenesis pathway gene polymorphisms for therapy selection |
EP2007602A4 (en) * | 2006-03-31 | 2010-09-22 | Centocor Ortho Biotech Inc | HUMAN EPO MIMETICS IN HINGED CENTRAL REGION, COMPOSITIONS, METHODS AND USES IN THE PREVENTION OR TREATMENT OF GLUCOSE INTOLERANCE OR ANEMIA ASSOCIATED WITH NEPHROPATHY |
KR20090029184A (ko) * | 2006-04-07 | 2009-03-20 | 더 가브먼트 오브 더 유나이티드 스테이츠 오브 아메리카, 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 | 항체 조성물 및 신생물성 질병의 치료 방법 |
US8784810B2 (en) | 2006-04-18 | 2014-07-22 | Janssen Alzheimer Immunotherapy | Treatment of amyloidogenic diseases |
EP2035454A2 (en) * | 2006-05-19 | 2009-03-18 | Amgen, Inc. | Antibodies to sars coronavirus |
BRPI0712607A8 (pt) | 2006-05-25 | 2019-06-04 | Biogen Idec Inc | métodos de tratamento de acidente vascular cerebral |
FR2901707B1 (fr) | 2006-05-31 | 2017-09-29 | Lab Francais Du Fractionnement | Composition de facteur vii recombinant ou transgenique, chaque molecule de facteur vii possedant deux sites de n-glycosylation a motifs glycanniques definis |
AU2007345745C1 (en) * | 2006-06-19 | 2013-05-23 | Merck Sharp & Dohme Corp. | ILT3 binding molecules and uses therefor |
KR20090027241A (ko) | 2006-07-10 | 2009-03-16 | 바이오겐 아이덱 엠에이 인코포레이티드 | Smad4-결핍 암의 성장을 억제하기 위한 조성물 및 방법 |
FR2904558B1 (fr) * | 2006-08-01 | 2008-10-17 | Lab Francais Du Fractionnement | "composition de facteur vii recombinant ou transgenique, presentant majoritairement des formes glycanniques biantennees, bisialylees et non fucosylees" |
SI2511301T1 (en) | 2006-08-04 | 2018-05-31 | MedImmune Limited, | Human antibodies to ERBB 2 |
CN101506237B (zh) * | 2006-08-22 | 2014-05-07 | G2炎症私人有限公司 | 具有改进性能的抗-C5aR抗体 |
TR201910145T4 (tr) | 2006-09-26 | 2019-08-21 | Genmab As | Tümörlerin tedavi edilmesine yönelik anti-CD38 artı kortikosteroidler artı bir kortikosteroid-olmayan kemoterapötik. |
AU2007308145A1 (en) * | 2006-10-12 | 2008-04-17 | Wyeth | Modification of ionic strength in antibody-solutions to reduce opalescence/aggregates |
WO2008052796A1 (en) | 2006-11-03 | 2008-05-08 | U3 Pharma Gmbh | Fgfr4 antibodies |
AR064623A1 (es) * | 2006-12-21 | 2009-04-15 | Centocor Inc | Uso de agonistas del receptor de glp -1 de accion prolongada para mejorar la sensibilidad a la insulina y los perfiles lipidicos |
US8440185B2 (en) * | 2006-12-26 | 2013-05-14 | The Johns Hopkins University | Compositions and methods for the treatment of immunologic disorders |
AU2007339762B2 (en) * | 2006-12-27 | 2011-03-31 | The Johns Hopkins University | Compositions and methods for treating inflammation and auto-immune diseases |
US7989173B2 (en) * | 2006-12-27 | 2011-08-02 | The Johns Hopkins University | Detection and diagnosis of inflammatory disorders |
US20090142342A1 (en) * | 2006-12-27 | 2009-06-04 | Johns Hopkins University | B7-h4 receptor agonist compositions and methods for treating inflammation and auto-immune diseases |
FR2910786B1 (fr) * | 2006-12-29 | 2017-08-11 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies (Lfb) | "procede d'extraction d'une proteine presente dans du lait" |
CA2675366A1 (en) * | 2007-01-18 | 2008-07-24 | University Of Southern California | Gene polymorphisms predictive for dual tki therapy |
CA2678963C (en) | 2007-02-23 | 2018-05-01 | Elan Pharmaceuticals, Inc. | Prevention and treatment of synucleinopathic and amyloidogenic disease |
PT2118300E (pt) | 2007-02-23 | 2015-09-22 | Univ California | Prevenção e tratamento da doença sinucleinopática e amiloidogénica |
MX2009010120A (es) | 2007-03-22 | 2009-10-19 | Ucb Pharma Sa | Proteinas de union, incluyendo anticuerpos, derivados de anticuerpo y fragmentos de anticuerpo, que se unen especificamente cd154 y sus usos. |
ES2593484T3 (es) | 2007-03-29 | 2016-12-09 | Genmab A/S | Anticuerpos biespecíficos y métodos de producción de los mismos |
US8003097B2 (en) | 2007-04-18 | 2011-08-23 | Janssen Alzheimer Immunotherapy | Treatment of cerebral amyloid angiopathy |
FR2915398B1 (fr) * | 2007-04-25 | 2012-12-28 | Lab Francais Du Fractionnement | "ensemble de moyens pour le traitement d'une pathologie maligne, d'une maladie auto-immune ou d'une maladie infectieuse" |
CA2688275A1 (en) | 2007-05-31 | 2008-12-04 | Genmab A/S | Stable igg4 antibodies |
PT2170390T (pt) * | 2007-06-14 | 2019-02-12 | Biogen Ma Inc | Formulações com anticorpo natalizumab |
EP3124046B1 (en) | 2007-07-12 | 2019-12-25 | GITR, Inc. | Combination therapies employing gitr binding molecules |
EP2215474A4 (en) * | 2007-07-16 | 2012-07-18 | Avaxia Biologics Inc | ANTIBODY THERAPY FOR MODULATING THE FUNCTION OF DARM RECEPTORS |
SI2182983T1 (sl) | 2007-07-27 | 2014-09-30 | Janssen Alzheimer Immunotherapy | Zdravljenje amiloidogenih bolezni s humaniziranimi protitelesi proti abeta |
US8268783B2 (en) | 2007-09-28 | 2012-09-18 | Portola Pharmaceuticals, Inc. | Antidotes for factor Xa inhibitors and methods of using the same |
CA2697583C (en) | 2007-09-28 | 2016-04-12 | Portola Pharmaceuticals, Inc. | Antidotes for factor xa inhibitors and methods of using the same |
CA2734139C (en) | 2007-10-02 | 2019-12-24 | Avaxia Biologics, Inc. | Antibody therapy for use in the digestive tract |
JO3076B1 (ar) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
EP2214708A4 (en) | 2007-10-26 | 2011-01-12 | Centocor Ortho Biotech Inc | VECTORS, HOST CELLS, METHODS OF PRODUCTION AND USES |
CA2705164A1 (en) | 2007-11-12 | 2009-05-22 | U3 Pharma Gmbh | Axl antibodies |
US20090169549A1 (en) * | 2007-12-19 | 2009-07-02 | The Board Of Regents Of The University Of Texas System | Conformational isomers of alpha-synuclein, antibodies thereto and methods of their manufacture and use |
MX2010007530A (es) | 2008-01-10 | 2010-11-10 | Res Dev Foundation | Vacunas y diagnosticos para ehrlichiosis. |
WO2009103113A1 (en) * | 2008-02-20 | 2009-08-27 | G2 Inflammation Pty Ltd | HUMANIZED ANTI-C5aR ANTIBODIES |
US8962803B2 (en) | 2008-02-29 | 2015-02-24 | AbbVie Deutschland GmbH & Co. KG | Antibodies against the RGM A protein and uses thereof |
KR102072896B1 (ko) | 2008-04-25 | 2020-02-03 | 다이액스 코포레이션 | Fcrn에 대한 항체 및 이들의 용도 |
US20110229460A1 (en) * | 2008-05-01 | 2011-09-22 | Gtc Biotherapeutics, Inc. | anti-cd137 antibody as an agent in the treatment of inflammatory conditions |
BRPI0913007A2 (pt) | 2008-05-02 | 2019-09-24 | Novartis Ag | moléculas de ligação aprimoradas à base de fibronectina e usos das mesmas |
MX2010012963A (es) | 2008-05-30 | 2011-04-05 | Xbiotech Inc | Anticuerpos de interleucina-1 alfa y metodos de uso. |
PT3444274T (pt) | 2008-06-25 | 2021-03-17 | Novartis Ag | Anticorpos que inibem tnf estáveis e solúveis |
ES2677003T3 (es) | 2008-06-25 | 2018-07-27 | Esbatech, An Alcon Biomedical Research Unit Llc | Humanización de anticuerpos de conejo utilizando un marco universal de anticuerpos |
NO2824100T3 (ja) | 2008-07-08 | 2018-07-21 | ||
EP2318048B1 (en) * | 2008-07-21 | 2019-05-29 | Immunomedics, Inc. | Structural variants of antibodies for improved therapeutic characteristics |
WO2010019656A1 (en) * | 2008-08-12 | 2010-02-18 | Wyeth | Humanized anti-rage antibody |
AU2009281713B9 (en) | 2008-08-14 | 2014-05-29 | Teva Pharmaceuticals Australia Pty Ltd | Anti-IL-12/IL-23 antibodies |
WO2010036978A2 (en) * | 2008-09-25 | 2010-04-01 | Transgenrx, Inc. | Novel vectors for production of growth hormone |
WO2010036979A2 (en) * | 2008-09-25 | 2010-04-01 | Transgenrx, Inc. | Novel vectors for production of interferon |
WO2010036976A2 (en) * | 2008-09-25 | 2010-04-01 | Transgenrx, Inc. | Novel vectors for production of antibodies |
JP2012505900A (ja) | 2008-10-14 | 2012-03-08 | ダイアクス コーポレーション | 全身性強皮症に伴う肺線維症の治療および予防のためのigf−ii/igf−iie結合タンパク質の使用 |
US9067981B1 (en) | 2008-10-30 | 2015-06-30 | Janssen Sciences Ireland Uc | Hybrid amyloid-beta antibodies |
UA109633C2 (uk) | 2008-12-09 | 2015-09-25 | Антитіло людини проти тканинного фактора | |
EP2376117A1 (en) | 2008-12-17 | 2011-10-19 | Genentech, Inc. | Hepatitis c virus combination therapy |
JP4981826B2 (ja) * | 2009-01-28 | 2012-07-25 | シャープ株式会社 | 通信システム、画像形成装置及び携帯情報端末装置 |
US9150881B2 (en) * | 2009-04-09 | 2015-10-06 | Proteovec Holding, L.L.C. | Production of proteins using transposon-based vectors |
WO2010121141A1 (en) * | 2009-04-17 | 2010-10-21 | Biogen Idec Ma Inc. | Compositions and methods to treat acute myelogenous leukemia |
EP2270053A1 (en) | 2009-05-11 | 2011-01-05 | U3 Pharma GmbH | Humanized AXL antibodies |
US20100304873A1 (en) * | 2009-05-28 | 2010-12-02 | Lipa Markowitz | Bowling Ball and Football Game Controller |
US8399625B1 (en) | 2009-06-25 | 2013-03-19 | ESBATech, an Alcon Biomedical Research Unit, LLC | Acceptor framework for CDR grafting |
CA2767858C (en) | 2009-07-15 | 2019-02-12 | Portola Pharmaceuticals, Inc. | Unit dose formulation of antidotes for factor xa inhibitors and methods of using the same |
US9005616B2 (en) | 2009-08-31 | 2015-04-14 | Amplimmune, Inc. | Methods and compositions for the inhibition of transplant rejection |
CN102482701B (zh) | 2009-09-16 | 2015-05-13 | 免疫医疗公司 | I类抗-cea抗体及其使用 |
WO2011044553A1 (en) | 2009-10-11 | 2011-04-14 | Biogen Idec Ma Inc. | Anti-vla-4 related assays |
EA030827B1 (ru) | 2009-10-23 | 2018-10-31 | Милленниум Фармасьютикалз, Инк. | Анти-gcc антитело и его применения |
WO2011051327A2 (en) | 2009-10-30 | 2011-05-05 | Novartis Ag | Small antibody-like single chain proteins |
WO2011051466A1 (en) | 2009-11-02 | 2011-05-05 | Novartis Ag | Anti-idiotypic fibronectin-based binding molecules and uses thereof |
SG181563A1 (en) | 2009-12-08 | 2012-07-30 | Abbott Gmbh & Co Kg | Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration |
CA3168591A1 (en) | 2010-01-06 | 2011-07-14 | Takeda Pharmaceutical Company Limited | Plasma kallikrein binding proteins |
US9796788B2 (en) | 2010-02-08 | 2017-10-24 | Regeneron Pharmaceuticals, Inc. | Mice expressing a limited immunoglobulin light chain repertoire |
ES2603559T5 (es) | 2010-02-08 | 2021-02-22 | Regeneron Pharma | Cadena ligera común de ratón |
US20130045492A1 (en) | 2010-02-08 | 2013-02-21 | Regeneron Pharmaceuticals, Inc. | Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain |
CN102933231B (zh) | 2010-02-10 | 2015-07-29 | 伊缪诺金公司 | Cd20抗体及其用途 |
PT3202789T (pt) | 2010-04-16 | 2020-06-16 | Biogen Ma Inc | Anticorpos anti-vla-4 |
EP2384766A1 (en) | 2010-05-03 | 2011-11-09 | Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Novel antibody to a carbonic anhydrase |
SI2580243T1 (sl) | 2010-06-09 | 2020-02-28 | Genmab A/S | Protitelesa proti humanemu CD38 |
AU2011267106B2 (en) | 2010-06-15 | 2015-05-14 | Genmab A/S | Human antibody drug conjugates against tissue factor |
CA2801210C (en) | 2010-06-19 | 2020-07-21 | Memorial Sloan-Kettering Cancer Center | Anti-gd2 antibodies |
EA201291328A1 (ru) | 2010-06-22 | 2013-10-30 | Дзе Риджентс Оф Дзе Юниверсити Оф Колорадо, Э Боди Корпорейт | АНТИТЕЛА К ФРАГМЕНТУ C3d КОМПОНЕНТА КОМПЛЕМЕНТА 3 |
EP2591099B1 (en) | 2010-07-09 | 2020-11-18 | Bioverativ Therapeutics Inc. | Chimeric clotting factors |
JP2013536175A (ja) | 2010-07-16 | 2013-09-19 | アブリンクス エン.ヴェー. | 修飾された単一ドメイン抗原結合分子及びその使用 |
FR2962908A1 (fr) | 2010-07-20 | 2012-01-27 | Lfb Biotechnologies | Formulation d'anticorps anti-cd20 |
WO2012019061A2 (en) | 2010-08-05 | 2012-02-09 | Stem Centrx, Inc. | Novel effectors and methods of use |
CA2805361A1 (en) | 2010-09-29 | 2012-04-05 | Universite De Liege | Combination of an agonistic anti-cd40 monoclonal antibody or a cd40 ligand and inactivated or attenuated bacteria for use in the treatment and/or prevention of mastitis |
UY33679A (es) | 2010-10-22 | 2012-03-30 | Esbatech | Anticuerpos estables y solubles |
PE20180249A1 (es) | 2010-11-19 | 2018-02-02 | Eisai Randd Man Co Ltd | Anticuerpos neutralizadores anti-ccl20 |
SG191781A1 (en) | 2010-12-30 | 2013-08-30 | Lab Francais Du Fractionnement | Glycols as pathogen inactivating agents |
ES2899186T3 (es) | 2010-12-31 | 2022-03-10 | Bioatla Inc | Humanización rápida de anticuerpos |
JP2014506257A (ja) | 2011-01-06 | 2014-03-13 | ダイアックス コーポレーション | 血漿カリクレイン結合タンパク質 |
SA112330278B1 (ar) | 2011-02-18 | 2015-10-09 | ستيم سينتركس، انك. | مواد ضابطة جديدة وطرق للاستخدام |
WO2012122512A1 (en) | 2011-03-10 | 2012-09-13 | Hco Antibody, Inc. | Recombinant production of mixtures of single chain antibodies |
JP6130350B2 (ja) | 2011-03-30 | 2017-05-17 | アブリンクス エン.ヴェー. | TNFαに対する単一ドメイン抗体で免疫障害を処置する方法 |
WO2012136552A1 (en) | 2011-04-08 | 2012-10-11 | H. Lundbeck A/S | ANTIBODIES SPECIFIC TO PYROGLUTAMATED Αβ |
WO2012142164A1 (en) | 2011-04-12 | 2012-10-18 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Human monoclonal antibodies that bind insulin-like growth factor (igf) i and ii |
CN105601741A (zh) | 2011-04-15 | 2016-05-25 | 卡姆普根有限公司 | 多肽和多核苷酸及其用于治疗免疫相关失调和癌症的用途 |
SG10201604493TA (en) | 2011-06-02 | 2016-07-28 | Dyax Corp | Fc RECEPTOR BINDING PROTEINS |
CN103596982B (zh) | 2011-06-06 | 2016-11-02 | 诺沃—诺迪斯克有限公司 | 治疗性抗体 |
US9738707B2 (en) | 2011-07-15 | 2017-08-22 | Biogen Ma Inc. | Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto |
SI3572517T1 (sl) | 2011-08-05 | 2021-09-30 | Regeneron Pharmaceuticals, Inc. | Humanizirana miš z univerzalno lahko verigo |
JP6317670B2 (ja) | 2011-08-15 | 2018-04-25 | ザ・ユニバーシティ・オブ・シカゴThe University Of Chicago | ブドウ球菌プロテインaに対する抗体に関連した組成物および方法 |
US20130058947A1 (en) | 2011-09-02 | 2013-03-07 | Stem Centrx, Inc | Novel Modulators and Methods of Use |
ES2942483T3 (es) | 2011-10-05 | 2023-06-01 | Oned Mat Inc | Materiales activos de nanoestructuras de silicio para baterías de iones de litio y procesos, composiciones, componentes y dispositivos relacionados con los mismos |
DK2581387T3 (en) | 2011-10-11 | 2015-12-07 | Université D Aix Marseille | An anti-HIV-1 Tat monoclonal antibody |
RU2014114015A (ru) | 2011-11-08 | 2015-12-20 | Пфайзер Инк. | Способы лечения воспалительных расстройств с использованием антител против m-csf |
MX2014006272A (es) | 2011-11-23 | 2014-10-24 | Igenica Biotherapeutics Inc | Anticuerpos anti-cd98 y metodos de uso de los mismos. |
EP2791175A2 (en) | 2011-12-14 | 2014-10-22 | Abbvie Deutschland GmbH & Co. KG | Composition and method for the diagnosis and treatment of iron-related disorders |
CA2855840C (en) | 2011-12-14 | 2023-08-29 | AbbVie Deutschland GmbH & Co. KG | Composition and method for the diagnosis and treatment of iron-related disorders |
MX350378B (es) | 2012-01-10 | 2017-09-05 | Biogen Ma Inc | Mejora del transporte de moleculas terapeuticas a traves de la barrera hematoencefalica. |
RU2644337C2 (ru) | 2012-01-27 | 2018-02-08 | Эббви Дойчланд Гмбх Унд Ко. Кг | Композиции и способы диагностики и лечения заболеваний, ассоциированных с дегенерацией нейритов |
JP6345123B2 (ja) | 2012-02-16 | 2018-06-20 | サンタラス, インコーポレイテッド | 抗vla1(cd49a)抗体医薬組成物 |
RU2014138474A (ru) | 2012-02-24 | 2016-04-10 | СтемСентРкс, Инк. | Новые модуляторы и способы применения |
JP6200437B2 (ja) | 2012-03-16 | 2017-09-20 | ユニバーシティ ヘルス ネットワーク | Toso活性を調節するための方法および組成物 |
SI2828284T1 (sl) | 2012-03-20 | 2019-10-30 | Biogen Ma Inc | Virus JC nevtralizirajoča protitelesa |
PT2838918T (pt) | 2012-04-20 | 2019-08-23 | Merus Nv | Métodos e meios para a produção de moléculas heterrodiméricas do tipo ig |
US9156915B2 (en) | 2012-04-26 | 2015-10-13 | Thomas Jefferson University | Anti-GCC antibody molecules |
CA2910320A1 (en) | 2012-04-26 | 2013-10-31 | University Of Chicago | Compositions and methods related to antibodies that neutralize coagulase activity during staphylococcus aureus disease |
US9969794B2 (en) | 2012-05-10 | 2018-05-15 | Visterra, Inc. | HA binding agents |
EP3492101A3 (en) | 2012-05-10 | 2019-10-23 | Massachusetts Institute Of Technology | Agents for influenza neutralization |
EP3508497A1 (en) | 2012-05-24 | 2019-07-10 | Mountgate Group Limited | Compositions and methods related to prevention and treatment of rabies infection |
EP2863940A4 (en) | 2012-06-08 | 2016-08-10 | Biogen Ma Inc | CHIMERIC COAGULATION FACTORS |
MY177331A (en) | 2012-06-15 | 2020-09-12 | Pfizer | Improved antagonist antibodies against gdf-8 and uses therefor |
WO2014022748A1 (en) | 2012-08-03 | 2014-02-06 | Revo Biologics, Inc. | The use of antithrombin in extracorporeal membrane oxygenation |
SG11201500605TA (en) | 2012-08-07 | 2015-02-27 | Massachusetts Inst Technology | Anti-dengue virus antibodies and uses thereof |
UA118441C2 (uk) | 2012-10-08 | 2019-01-25 | Протена Біосаєнсиз Лімітед | Антитіло, що розпізнає альфа-синуклеїн |
JP2015533832A (ja) | 2012-10-09 | 2015-11-26 | アイジェニカ バイオセラピューティクス インコーポレイテッド | 抗C16orf54抗体およびその使用方法 |
NZ708033A (en) | 2012-12-10 | 2020-03-27 | Biogen Ma Inc | Anti-blood dendritic cell antigen 2 antibodies and uses thereof |
TWI635098B (zh) | 2013-02-01 | 2018-09-11 | 再生元醫藥公司 | 含嵌合恆定區之抗體 |
AU2013378628A1 (en) | 2013-02-15 | 2015-06-11 | Esbatech - A Novartis Company Llc | Acceptor framework for CDR grafting |
HRP20231183T1 (hr) | 2013-02-15 | 2024-01-05 | Bioverativ Therapeutics Inc. | Optimizirani gen faktora viii |
JP2016506752A (ja) | 2013-02-20 | 2016-03-07 | エスバテック − ア ノバルティスカンパニー エルエルシー | Cdrグラフトのためのアクセプターフレームワーク |
WO2014130922A1 (en) | 2013-02-25 | 2014-08-28 | Trustees Of Boston University | Compositions and methods for treating fungal infections |
US10167341B2 (en) | 2013-03-15 | 2019-01-01 | Memorial Sloan Kettering Cancer Center | High affinity anti-GD2 antibodies |
ES2935257T3 (es) | 2013-03-15 | 2023-03-03 | Univ Chicago | Métodos y composiciones relacionadas con la actividad de las células T |
SG10201707600XA (en) | 2013-03-15 | 2017-11-29 | Biogen Ma Inc | Factor ix polypeptide formulations |
CA2903546A1 (en) | 2013-03-15 | 2014-09-25 | Biogen Ma Inc. | Treatment and prevention of acute kidney injury using anti-alpha v beta 5 antibodies |
US10035860B2 (en) | 2013-03-15 | 2018-07-31 | Biogen Ma Inc. | Anti-alpha V beta 6 antibodies and uses thereof |
WO2014144466A1 (en) | 2013-03-15 | 2014-09-18 | Biogen Idec Ma Inc. | Anti-alpha v beta 6 antibodies and uses thereof |
US9469686B2 (en) | 2013-03-15 | 2016-10-18 | Abbott Laboratories | Anti-GP73 monoclonal antibodies and methods of obtaining the same |
WO2014197723A2 (en) | 2013-06-05 | 2014-12-11 | Massachusetts Institute Of Technology | Human adaptation of h7 ha |
US10183988B2 (en) | 2013-06-07 | 2019-01-22 | Duke University | Anti-Complement factor H antibodies |
JP6566941B2 (ja) | 2013-06-28 | 2019-08-28 | ベイラー リサーチ インスティテュートBaylor Research Institute | 多発性硬化症のための樹状細胞asgpr標的化免疫治療薬 |
AU2014285971A1 (en) | 2013-07-05 | 2016-02-04 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Affinity chromatography matrix |
WO2015003114A1 (en) | 2013-07-05 | 2015-01-08 | University Of Washington Through Its Center For Commercialization | Soluble mic neutralizing monoclonal antibody for treating cancer |
WO2015004633A1 (en) | 2013-07-12 | 2015-01-15 | Neotope Biosciences Limited | Antibodies that recognize islet-amyloid polypeptide (iapp) |
US9850302B2 (en) | 2013-07-12 | 2017-12-26 | Prothena Biosciences Limited | Antibodies that recognize IAPP |
JP2016538318A (ja) | 2013-08-28 | 2016-12-08 | ステムセントリックス, インコーポレイテッド | 新規sez6モジュレーターおよび使用方法 |
WO2015057939A1 (en) | 2013-10-18 | 2015-04-23 | Biogen Idec Ma Inc. | Anti-s1p4 antibodies and uses thereof |
JP6657098B2 (ja) | 2013-10-21 | 2020-03-04 | ダイアックス コーポレーション | 自己免疫疾患の診断と治療 |
WO2015097536A2 (en) | 2013-12-24 | 2015-07-02 | Janssen Pharmaceutical Nv | Anti-vista antibodies and fragments |
EP3094652B1 (en) | 2014-01-13 | 2021-09-29 | Baylor Research Institute | Novel vaccines against hpv and hpv-related diseases |
ES2856076T3 (es) | 2014-01-21 | 2021-09-27 | Takeda Pharmaceuticals Co | Proteínas de unión a calicreína plasmática y usos de las mismas en el tratamiento de angioedema hereditario |
MX2016009555A (es) | 2014-01-24 | 2016-12-08 | Ngm Biopharmaceuticals Inc | Proteinas de union y metodos para utilizarlas. |
CN106170497A (zh) | 2014-02-07 | 2016-11-30 | 免疫医疗有限责任公司 | 检测人类骨膜蛋白的新型测定 |
CN106413749B (zh) | 2014-02-11 | 2022-04-05 | 麻省理工学院 | 新颖全谱抗登革抗体 |
CA2941693A1 (en) | 2014-03-07 | 2015-09-11 | University Health Network | Methods and compositions for detection of targets involved in cancer metastasis |
EP3116907A1 (en) | 2014-03-12 | 2017-01-18 | Prothena Biosciences Limited | Anti-laminin4 antibodies specific for lg4-5 |
EP3116906A1 (en) | 2014-03-12 | 2017-01-18 | Prothena Biosciences Limited | Anti-laminin4 antibodies specific for lg1-3 |
CA2942697A1 (en) | 2014-03-21 | 2015-09-24 | Lynn Macdonald | Non-human animals that make single domain binding proteins |
KR102555955B1 (ko) | 2014-03-27 | 2023-07-18 | 다케다 파머수티컬 컴패니 리미티드 | 당뇨병성 황반 부종의 치료를 위한 조성물 및 방법 |
US10562973B2 (en) | 2014-04-08 | 2020-02-18 | Prothena Bioscience Limited | Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein |
JP2017518737A (ja) | 2014-04-21 | 2017-07-13 | ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. | SYK標的治療薬のための抗pSYK抗体分子及びその使用 |
NL2013007B1 (en) | 2014-06-16 | 2016-07-05 | Ablynx Nv | Methods of treating TTP with immunoglobulin single variable domains and uses thereof. |
EP3160478A4 (en) | 2014-06-30 | 2018-05-16 | Bioverativ Therapeutics Inc. | Optimized factor ix gene |
WO2016007414A1 (en) | 2014-07-08 | 2016-01-14 | New York University | Tau imaging ligands and their uses in the diagnosis and treatment of tauopathy |
WO2018140026A1 (en) | 2017-01-27 | 2018-08-02 | Memorial Sloan Kettering Cancer Center | Bispecific her2 and cd3 binding molecules |
KR102523984B1 (ko) | 2014-08-15 | 2023-04-20 | 주식회사 제넥신 | 자궁경부 종양의 치료 방법 |
EP3186277B1 (en) | 2014-08-27 | 2020-10-07 | Memorial Sloan Kettering Cancer Center | Antibodies, compositions, and uses |
FR3025515B1 (fr) | 2014-09-05 | 2016-09-09 | Lab Francais Du Fractionnement | Procede de purification d'un anticorps monoclonal |
ES2748295T3 (es) | 2014-09-16 | 2020-03-16 | Symphogen As | Anticuerpos anti-MET y composiciones |
EP3201226A2 (en) | 2014-10-03 | 2017-08-09 | Massachusetts Institute of Technology | Antibodies that bind ebola glycoprotein and uses thereof |
MA40835A (fr) | 2014-10-23 | 2017-08-29 | Biogen Ma Inc | Anticorps anti-gpiib/iiia et leurs utilisations |
MA40861A (fr) | 2014-10-31 | 2017-09-05 | Biogen Ma Inc | Anticorps anti-glycoprotéines iib/iiia |
TWI711631B (zh) | 2015-01-28 | 2020-12-01 | 愛爾蘭商普羅佘納生物科技有限公司 | 抗甲狀腺素運送蛋白抗體 |
TWI786505B (zh) | 2015-01-28 | 2022-12-11 | 愛爾蘭商普羅佘納生物科技有限公司 | 抗甲狀腺素運送蛋白抗體 |
TWI781507B (zh) | 2015-01-28 | 2022-10-21 | 愛爾蘭商普羅佘納生物科技有限公司 | 抗甲狀腺素運送蛋白抗體 |
JP6970017B2 (ja) | 2015-02-09 | 2021-11-24 | メモリアル スローン ケタリング キャンサー センター | ヒトa33抗原とdota金属複合体に親和性を有する多重特異性抗体及びその使用 |
CA2979976A1 (en) | 2015-03-17 | 2016-09-22 | Memorial Sloan Kettering Cancer Center | Anti-muc16 antibodies and uses thereof |
EP3271397B1 (en) | 2015-03-18 | 2021-03-03 | The Johns Hopkins University | Inhibitory monoclonal antibody targeting potassium channel kcnk9 |
EP3271403A1 (en) | 2015-03-19 | 2018-01-24 | Regeneron Pharmaceuticals, Inc. | Non-human animals that select for light chain variable regions that bind antigen |
US20180298110A1 (en) | 2015-03-30 | 2018-10-18 | Dyax Corp. | Plasma kallikrein inhibitors and uses thereof for preventing hereditary angioedema attack |
FR3034420A1 (fr) | 2015-03-31 | 2016-10-07 | Lab Francais Du Fractionnement | Anticorps monoclonaux anti-cd303 |
FR3034419B1 (fr) | 2015-04-02 | 2017-12-15 | Lab Francais Du Fractionnement | Procede de purification d'une proteine recombinante therapeutique a partir d'un lait transgenique |
EP3313882B1 (en) | 2015-06-24 | 2020-03-11 | Janssen Pharmaceutica NV | Anti-vista antibodies and fragments |
US10287338B2 (en) | 2015-07-10 | 2019-05-14 | Miran NERSISSIAN | Factor VIII protein compositions and methods of treating of hemophilia A |
JO3711B1 (ar) | 2015-07-13 | 2021-01-31 | H Lundbeck As | أجسام مضادة محددة لبروتين تاو وطرق استعمالها |
GB201512215D0 (en) | 2015-07-13 | 2015-08-19 | Lundbeck & Co As H | Agents,uses and methods |
GB201512203D0 (en) | 2015-07-13 | 2015-08-19 | Lundbeck & Co As H | Agents,uses and methods |
WO2017023863A1 (en) | 2015-07-31 | 2017-02-09 | Research Institute At Nationwide Children's Hospital | Peptides and antibodies for the removal of biofilms |
MX2018001497A (es) | 2015-08-03 | 2018-05-15 | Bioverativ Therapeutics Inc | Proteinas de fusion de factor ix y metodos para producirlas y usarlas. |
EP3334761B1 (en) | 2015-08-13 | 2023-07-19 | New York University | Antibody-based molecules selective for the {p}ser404 epitope of tau and their uses in the diagnosis and treatment of tauopathy |
WO2017027685A2 (en) | 2015-08-13 | 2017-02-16 | New York University | Antibody-based molecules specific for the truncated asp421 epitope of tau and their uses in the diagnosis and treatment of tauopathy |
ES2890073T3 (es) | 2015-08-25 | 2022-01-17 | Prothena Biosciences Ltd | Métodos para detectar alfa-sinucleína fosforilada |
KR20180054824A (ko) | 2015-09-29 | 2018-05-24 | 셀진 코포레이션 | Pd-1 결합 단백질 및 이의 사용 방법 |
EP3365027B1 (en) | 2015-10-14 | 2022-03-30 | Research Institute at Nationwide Children's Hospital | Hu specific antibodies and their use in inhibiting biofilm |
WO2017083627A1 (en) | 2015-11-13 | 2017-05-18 | Visterra, Inc. | Compositions and methods for treating and preventing influenza |
ES2902477T3 (es) | 2015-12-04 | 2022-03-28 | Univ Texas | Péptidos SLC45A2 para inmunoterapia |
EP3387018A1 (en) | 2015-12-11 | 2018-10-17 | Dyax Corp. | Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack |
SI3411478T1 (sl) | 2016-02-01 | 2022-10-28 | Bioverativ Therapeutics Inc. | Optimirani geni dejavnika VIII |
US10465003B2 (en) | 2016-02-05 | 2019-11-05 | Janssen Biotech, Inc. | Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes |
MX2018009800A (es) | 2016-02-12 | 2018-11-09 | Janssen Pharmaceutica Nv | Anticuerpos y fragmentos anti-vista, usos de los mismos y procedimientos de identificacion de los mismos. |
JP7104629B2 (ja) | 2016-02-24 | 2022-07-21 | ビステラ, インコーポレイテッド | インフルエンザウイルスに対する抗体分子の製剤 |
SG10202009423QA (en) | 2016-03-28 | 2020-11-27 | Incyte Corp | Pyrrolotriazine compounds as tam inhibitors |
EA201892190A1 (ru) | 2016-03-29 | 2019-04-30 | Янссен Байотек, Инк. | Лечение псориаза антителом к ил-12 и/или ил-23 с возрастанием интервала между введениями дозы |
WO2017175058A1 (en) | 2016-04-07 | 2017-10-12 | Janssen Pharmaceutica Nv | Anti-vista antibodies and fragments, uses thereof, and methods of identifying same |
KR20230070336A (ko) | 2016-05-02 | 2023-05-22 | 프로테나 바이오사이언시즈 리미티드 | 타우 인식 항체 |
US10889638B2 (en) | 2016-05-02 | 2021-01-12 | Prothena Biosciences Limited | Antibodies recognizing tau |
EP3478714A2 (en) | 2016-07-02 | 2019-05-08 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
JP7016470B2 (ja) | 2016-07-02 | 2022-02-07 | プロセナ バイオサイエンシーズ リミテッド | 抗トランスサイレチン抗体 |
EP3478716A2 (en) | 2016-07-02 | 2019-05-08 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
CA3027350A1 (en) | 2016-07-06 | 2018-01-11 | Prothena Biosciences Limited | Assay for detecting total and s129 phosphorylated alpha-synuclein |
PE20190227A1 (es) | 2016-07-12 | 2019-02-13 | H Lundbeck As | Anticuerpos especificos para la tau hiperfosforilada y sus metodos de uso |
EP3487880A1 (en) | 2016-07-25 | 2019-05-29 | Biogen MA Inc. | Anti-hspa5 (grp78) antibodies and uses thereof |
EP3491136A1 (en) | 2016-07-28 | 2019-06-05 | Laboratoire Francais du Fractionnement et des Biotechnologies Societe Anonyme | Anti- immunoglobulin g aptamers and uses thereof |
EP3510046A4 (en) | 2016-09-07 | 2020-05-06 | The Regents of the University of California | ANTIBODIES AGAINST OXIDATION-SPECIFIC EPITOPES |
US10751414B2 (en) | 2016-09-19 | 2020-08-25 | Celgene Corporation | Methods of treating psoriasis using PD-1 binding antibodies |
EP3515943A4 (en) | 2016-09-19 | 2020-05-06 | Celgene Corporation | METHODS OF TREATING VITILIGO WITH PD-1 BINDING PROTEINS |
CA3037961A1 (en) | 2016-09-30 | 2018-04-05 | Janssen Biotech, Inc. | Safe and effective method of treating psoriasis with anti-il23 specific antibody |
US20180106800A1 (en) | 2016-10-03 | 2018-04-19 | Abbott Laboratories | Methods of assessing uch-l1 status in patient samples |
CA3040189A1 (en) | 2016-10-13 | 2018-04-19 | Massachusetts Institute Of Technology | Antibodies that bind zika virus envelope protein and uses thereof |
CA3043651A1 (en) | 2016-11-15 | 2018-05-24 | H. Lundbeck A/S | Agents, uses and methods for the treatment of synucleinopathy |
MA46861A (fr) | 2016-11-16 | 2019-09-25 | Janssen Biotech Inc | Procédé de traitement du psoriasis avec un anticorps anti-il-23 spécifique |
FR3060394B1 (fr) | 2016-12-16 | 2019-05-24 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Combinaison d'anticorps anti-cd303 et anti-amhrii |
JP7144755B2 (ja) | 2016-12-16 | 2022-09-30 | ハー・ルンドベック・アクチエゼルスカベット | 薬剤、使用および方法 |
WO2018109213A1 (en) | 2016-12-16 | 2018-06-21 | Laboratoire Français Du Fractionnement Et Des Biotechnologies | Aptamers directed against a kappa light chain-containing protein and uses thereof |
FR3060395B1 (fr) | 2016-12-16 | 2019-05-24 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Combinaison d'anticorps anti-cd303 et anti-her2 |
US10364286B2 (en) | 2016-12-22 | 2019-07-30 | H. Lundbeck A/S | Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation |
CN118047864A (zh) | 2016-12-23 | 2024-05-17 | 百时美施贵宝公司 | 用于改进生物分析和生物加工特性的治疗性免疫球蛋白g4的设计 |
CA3049114A1 (en) | 2017-01-04 | 2018-07-12 | Lauren O. Bakaletz | Antibody fragments for the treatment of biofilm-related disorders |
EP3565836A1 (en) | 2017-01-04 | 2019-11-13 | H. Lundbeck A/S | Antibodies specific for hyperphosphorylated tau for the treatment of ocular diseases |
EP3565589A1 (en) | 2017-01-04 | 2019-11-13 | Research Institute at Nationwide Children's Hospital | Dnabii vaccines and antibodies with enhanced activity |
US11773182B2 (en) | 2017-01-05 | 2023-10-03 | The Johns Hopkins University | Development of new monoclonal antibodies recognizing human prostate-specific membrane antigen (PSMA) |
WO2018140510A1 (en) | 2017-01-25 | 2018-08-02 | Biogen Ma Inc. | Compositions and methods for treatment of stroke and other cns disorders |
MX2019008989A (es) | 2017-01-30 | 2019-10-09 | Janssen Biotech Inc | Anticuerpos anti-tnf, composiciones y metodos para el tratamiento de la artritis psoriasica activa. |
TW201831521A (zh) | 2017-01-31 | 2018-09-01 | 美商生物化學醫療公司 | 因子ix融合蛋白以及其製備方法及使用方法 |
MX2019009377A (es) | 2017-02-07 | 2019-12-11 | Janssen Biotech Inc | Anticuerpos anti-tnf, composiciones y metodos para el tratamiento de la espondilitis anquilosante activa. |
WO2018170178A1 (en) | 2017-03-15 | 2018-09-20 | Research Institute At Nationwide Children's Hospital | Composition and methods for disruption of bacterial biofilms without accompanying inflammation |
FR3064007A1 (fr) | 2017-03-20 | 2018-09-21 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Anticorps pour le traitement de cancers |
CA3052513A1 (en) | 2017-03-23 | 2018-09-27 | Abbott Laboratories | Methods for aiding in the diagnosis and determination of the extent of traumatic brain injury in a human subject using the early biomarker ubiquitin carboxy-terminal hydrolase l1 |
JOP20190227A1 (ar) | 2017-03-31 | 2019-09-30 | Biogen Int Neuroscience Gmbh | تركيبات وطرق لعلاج اعتلالات السينوكلين |
EP3610268A1 (en) | 2017-04-15 | 2020-02-19 | Abbott Laboratories | Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury in a human subject using early biomarkers |
JP7080899B2 (ja) | 2017-04-28 | 2022-06-06 | アボット・ラボラトリーズ | 同じヒト対象に由来する少なくとも2つの試料に対して早期バイオマーカーを使用する、外傷性脳損傷の超急性の診断及び決定の一助となるための方法 |
WO2018204546A2 (en) | 2017-05-02 | 2018-11-08 | Prothena Biosciences Limited | Antibodies recognizing tau |
US10865238B1 (en) | 2017-05-05 | 2020-12-15 | Duke University | Complement factor H antibodies |
CA3078725A1 (en) | 2017-05-25 | 2018-11-29 | Abbott Laboratories | Methods for aiding in the determination of whether to perform imaging on a human subject who has sustained or may have sustained an injury to the head using early biomarkers |
AU2018275236A1 (en) | 2017-05-30 | 2019-10-31 | Abbott Laboratories | Methods for aiding in diagnosing and evaluating a mild traumatic brain injury in a human subject using cardiac troponin I |
AU2017418317A1 (en) | 2017-06-16 | 2019-12-05 | Bristol-Myers Squibb Company | Compositions and methods for treating tauopathies |
CA3065328C (en) | 2017-06-21 | 2023-08-15 | Gilead Sciences, Inc. | Multispecific antibodies that target hiv gp120 and cd3 |
US11169159B2 (en) | 2017-07-03 | 2021-11-09 | Abbott Laboratories | Methods for measuring ubiquitin carboxy-terminal hydrolase L1 levels in blood |
AU2018300189A1 (en) | 2017-07-14 | 2020-01-30 | Pfizer, Inc. | Antibodies to MAdCAM |
US10894833B2 (en) | 2017-07-20 | 2021-01-19 | H. Lundbeck A/S | Agents, uses and methods for treatment |
EP3444275A1 (en) | 2017-08-16 | 2019-02-20 | Exiris S.r.l. | Monoclonal antibody anti-fgfr4 |
WO2019040612A1 (en) | 2017-08-22 | 2019-02-28 | Biogen Ma Inc. | PHARMACEUTICAL COMPOSITIONS CONTAINING ANTI-BETA-AMYLOID ANTIBODIES |
US20210363259A1 (en) | 2017-08-22 | 2021-11-25 | Biogen Ma Inc. | Pharmaceutical compositions and dosage regimens containing anti-alpha(v)beta(6) antibodies |
US10759865B2 (en) | 2017-08-22 | 2020-09-01 | Eyal Levit | Treatment of diabetes mellitus |
TW201922780A (zh) | 2017-09-25 | 2019-06-16 | 美商健生生物科技公司 | 以抗il12/il23抗體治療狼瘡之安全且有效之方法 |
WO2019094595A2 (en) | 2017-11-09 | 2019-05-16 | Pinteon Therapeutics Inc. | Methods and compositions for the generation and use of humanized conformation-specific phosphorylated tau antibodies |
EP3710474A1 (en) | 2017-11-14 | 2020-09-23 | Bio-Sourcing S.A. | Antibody purification |
AU2018378084A1 (en) | 2017-12-09 | 2020-05-14 | Abbott Laboratories | Methods for aiding in diagnosing and evaluating a traumatic brain injury in a human subject using a combination of GFAP and UCH-L1 |
BR112019028254A2 (pt) | 2017-12-09 | 2020-07-14 | Abbott Laboratories | métodos para ajudar no diagnóstico e avaliação de um paciente que sofreu uma lesão ortopédica e que sofreu ou pode ter sofrido uma lesão na cabeça, tal como uma lesão cerebral traumática (lct) leve, usando a proteína ácida fibrilar glial (gfap) e/ou a hidrolase carbóxi-terminal da ubiquitina l1 (uch-l1) |
FR3076294B1 (fr) | 2017-12-29 | 2022-01-28 | Lab Francais Du Fractionnement | Procede de purification d'anticorps a partir de lait brut |
EP3732489A1 (en) | 2017-12-29 | 2020-11-04 | Abbott Laboratories | Novel biomarkers and methods for diagnosing and evaluating traumatic brain injury |
WO2019150309A1 (en) | 2018-02-02 | 2019-08-08 | Hammack Scott | Modulators of gpr68 and uses thereof for treating and preventing diseases |
CA3089211A1 (en) | 2018-02-06 | 2019-08-15 | Ablynx Nv | Methods of treating initial episode of ttp with immunoglobulin single variable domains |
CR20200441A (es) | 2018-02-27 | 2021-03-15 | Incyte Corp | Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a / a2b |
MA54132A (fr) | 2018-03-05 | 2022-04-27 | Janssen Biotech Inc | Méthodes de traitement de la maladie de crohn avec un anticorps spécifique anti-il23 |
US20210017295A1 (en) | 2018-03-12 | 2021-01-21 | Memorial Sloan Kettering Cancer Center | Bispecific binding agents and uses thereof |
WO2019213619A1 (en) | 2018-05-04 | 2019-11-07 | Abbott Laboratories | Hbv diagnostic, prognostic, and therapeutic methods and products |
AU2019266205A1 (en) | 2018-05-07 | 2020-10-22 | Genmab A/S | Methods of treating cancer with a combination of an anti-PD-1 antibody and an anti-tissue factor antibody-drug conjugate |
JP7460608B2 (ja) | 2018-05-07 | 2024-04-02 | ジェンマブ エー/エス | 抗pd-1抗体と抗組織因子抗体-薬物コンジュゲートとの組み合わせを用いるがんの治療方法 |
MA52590A (fr) | 2018-05-11 | 2021-03-17 | Janssen Biotech Inc | Méthodes de traitement de la dépression à l'aide d'anticorps il-23 |
MX2020012376A (es) | 2018-05-18 | 2021-03-09 | Incyte Corp | Derivados de pirimidina fusionados como inhibidores de los receptores de adenosina a2a/a2b. |
US20210238289A1 (en) | 2018-06-04 | 2021-08-05 | Biogen Ma Inc. | Anti-vla-4 antibodies having reduced effector function |
CN112955464A (zh) | 2018-06-20 | 2021-06-11 | 因赛特公司 | 抗pd-1抗体及其用途 |
TW202016144A (zh) | 2018-06-21 | 2020-05-01 | 日商第一三共股份有限公司 | 包括cd3抗原結合片段之組成物及其用途 |
US11241438B2 (en) | 2018-06-29 | 2022-02-08 | Incyte Corporation | Formulations of an AXL/MER inhibitor |
EP3817819A1 (en) | 2018-07-03 | 2021-05-12 | Gilead Sciences, Inc. | Antibodies that target hiv gp120 and methods of use |
JP2021530697A (ja) | 2018-07-18 | 2021-11-11 | ヤンセン バイオテツク,インコーポレーテツド | 抗il23特異的抗体で治療した後の持続応答予測因子 |
US11548938B2 (en) | 2018-08-21 | 2023-01-10 | Quidel Corporation | DbpA antibodies and uses thereof |
WO2020047352A1 (en) | 2018-08-30 | 2020-03-05 | Dyax Corp. | Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack |
US10961307B2 (en) | 2018-09-24 | 2021-03-30 | Janssen Biotech, Inc. | Methods of treating moderately to severely active ulcerative colitis by administering an anti-IL12/IL23 antibody |
EP3861023A1 (en) | 2018-10-04 | 2021-08-11 | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin | Humanised anti-n-truncated amyloid beta monoclonal antibody |
CA3114925A1 (en) | 2018-10-05 | 2020-04-09 | Research Institute At Nationwide Children's Hospital | Compositions and methods for enzymatic disruption of bacterial biofilms |
TW202034958A (zh) | 2018-10-30 | 2020-10-01 | 丹麥商珍美寶股份有限公司 | 使用抗血管內皮生長因子(vegf)抗體與抗組織因子(tf)抗體-藥物共軛體之組合以治療癌症之方法 |
AU2019383017A1 (en) | 2018-11-20 | 2021-06-03 | Janssen Biotech, Inc. | Safe and effective method of treating psoriasis with anti-IL-23 specific antibody |
US11208482B2 (en) | 2018-11-26 | 2021-12-28 | Forty Seven, Inc. | Humanized antibodies against c-Kit |
GB201820006D0 (en) | 2018-12-07 | 2019-01-23 | Lifearc | Humanised anti-IL17BR antibody |
US20200197517A1 (en) | 2018-12-18 | 2020-06-25 | Janssen Biotech, Inc. | Safe and Effective Method of Treating Lupus with Anti-IL12/IL23 Antibody |
CN113574066A (zh) | 2019-01-15 | 2021-10-29 | 詹森生物科技公司 | 用于治疗幼年特发性关节炎的抗tnf抗体组合物和方法 |
EA202192038A1 (ru) | 2019-01-23 | 2021-10-05 | Янссен Байотек, Инк. | Композиции антител к фно для применения в способах лечения псориатического артрита |
TWI829857B (zh) | 2019-01-29 | 2024-01-21 | 美商英塞特公司 | 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶 |
BR112021016947A2 (pt) | 2019-03-03 | 2021-11-03 | Prothena Biosciences Ltd | Anticorpos que reconhecem tau |
JP2022524768A (ja) | 2019-03-08 | 2022-05-10 | リンクシス ベスローテン フェンノートシャップ | 細胞増殖又は細胞分化に関与する受容体を標的にする内在化結合分子 |
MX2021010420A (es) | 2019-03-11 | 2021-11-12 | Biogen Ma Inc | Composiciones farmacéuticas que contienen anticuerpos antilingo-1. |
US20220144934A1 (en) | 2019-03-14 | 2022-05-12 | Janssen Biotech, Inc. | Methods for Producing Anti-TNF Antibody Compositions |
JP2022524860A (ja) | 2019-03-14 | 2022-05-10 | ヤンセン バイオテツク,インコーポレーテツド | 抗tnf抗体組成物を産生するための方法 |
EP3938404A1 (en) | 2019-03-14 | 2022-01-19 | Takeda Pharmaceutical Company Limited | Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack |
EP3938384A4 (en) | 2019-03-14 | 2022-12-28 | Janssen Biotech, Inc. | METHODS OF MANUFACTURING FOR PRODUCING ANTI-IL12/IL23 ANTIBODY COMPOSITIONS |
US20220153830A1 (en) | 2019-03-14 | 2022-05-19 | Janssen Biotech, Inc. | Manufacturing Methods for Producing Anti-TNF Antibody Compositions |
MA55383A (fr) | 2019-03-18 | 2022-01-26 | Janssen Biotech Inc | Méthode de traitement du psoriasis chez des sujets pédiatriques avec un anticorps anti-il12/il23 |
CN113924147A (zh) | 2019-03-25 | 2022-01-11 | 威特拉公司 | 用于治疗和预防流感的组合物和方法 |
JP2022527372A (ja) | 2019-04-08 | 2022-06-01 | バイオジェン・エムエイ・インコーポレイテッド | 抗インテグリン抗体及びそれらの使用 |
CN113874073A (zh) | 2019-05-23 | 2021-12-31 | 詹森生物科技公司 | 用针对IL-23和TNFα的抗体的联合疗法治疗炎性肠病的方法 |
CA3142665A1 (en) | 2019-06-03 | 2020-12-10 | Janssen Biotech, Inc. | Anti-tnf antibody compositions, and methods for the treatment of psoriatic arthritis |
WO2020245677A1 (en) | 2019-06-03 | 2020-12-10 | Janssen Biotech, Inc. | Anti-tnf antibodies, compositions, and methods for the treatment of active ankylosing spondylitis |
BR112021026376A2 (pt) | 2019-06-25 | 2022-05-10 | Gilead Sciences Inc | Proteínas de fusão flt3l-fc e métodos de uso |
MX2022000137A (es) | 2019-07-08 | 2022-05-19 | Res Inst Nationwide Childrens Hospital | Composiciones de anticuerpos para la ruptura de biopelículas. |
AU2020319875A1 (en) | 2019-08-01 | 2022-02-17 | Incyte Corporation | A dosing regimen for an IDO inhibitor |
WO2021028752A1 (en) | 2019-08-15 | 2021-02-18 | Janssen Biotech, Inc. | Anti-tfn antibodies for treating type i diabetes |
JP2022554356A (ja) | 2019-11-04 | 2022-12-28 | シージェン インコーポレイテッド | 抗cd30抗体薬物コンジュゲート及びhiv感染の処置のためのその使用 |
MX2022005222A (es) | 2019-11-07 | 2022-06-08 | Genmab As | Metodos para tratar el cancer con una combinacion de un anticuerpo anti muerte programada 1 (pd-1) y un conjugado de anticuerpo anti factor tisular-farmaco. |
TW202131954A (zh) | 2019-11-07 | 2021-09-01 | 丹麥商珍美寶股份有限公司 | 利用鉑類劑與抗組織因子抗體-藥物共軛體之組合來治療癌症之方法 |
US20230242655A1 (en) | 2019-12-03 | 2023-08-03 | Evotec International Gmbh | Interferon-associated antigen binding proteins and uses thereof |
WO2021110561A1 (en) | 2019-12-03 | 2021-06-10 | Evotec International Gmbh | Interferon-associated antigen binding proteins for use in treating hepatitis b infection |
US20230257449A1 (en) | 2019-12-11 | 2023-08-17 | Visterra, Inc. | Compositions and methods for treating and preventing influenza |
CN115298213A (zh) | 2019-12-19 | 2022-11-04 | 奎多公司 | 单克隆抗体融合 |
US20210230294A1 (en) | 2020-01-03 | 2021-07-29 | Incyte Corporation | Cd73 inhibitor and a2a/a2b adenosine receptor inhibitor combination therapy |
AU2020417813A1 (en) | 2020-01-03 | 2022-08-25 | Incyte Corporation | Combination therapy comprising A2A/A2B and PD-1/PD-L1 inhibitors |
WO2021138467A1 (en) | 2020-01-03 | 2021-07-08 | Incyte Corporation | Anti-cd73 antibodies and uses thereof |
CN115297927A (zh) | 2020-01-13 | 2022-11-04 | 武田药品工业株式会社 | 血浆激肽释放酶抑制剂及其用于治疗儿科遗传性血管性水肿发作的用途 |
CN115697343A (zh) | 2020-03-06 | 2023-02-03 | 因赛特公司 | 包含axl/mer和pd-1/pd-l1抑制剂的组合疗法 |
JP2023521667A (ja) | 2020-04-04 | 2023-05-25 | 武田薬品工業株式会社 | 血漿カリクレイン阻害剤及び急性呼吸窮迫症候群を処置するためのその使用 |
EP4136459A1 (en) | 2020-04-13 | 2023-02-22 | Abbott Laboratories | Methods, complexes and kits for detecting or determining an amount of a ss-coronavirus antibody in a sample |
KR20220109444A (ko) | 2020-04-24 | 2022-08-04 | 주식회사 제넥신 | 자궁경부암 치료방법 |
KR20230004520A (ko) | 2020-04-27 | 2023-01-06 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 지단백(a)에 대한 이소형-비의존성 항체 |
EP3909601A1 (en) | 2020-05-11 | 2021-11-17 | LeukoCom GmbH | A novel antibody binding specifically to human ceacam1/3/5 and use thereof |
BR112022025105A2 (pt) | 2020-06-29 | 2023-01-17 | Genmab As | Método para o tratamento de câncer cervical em um indivíduo, conjugado anticorpo-fármaco, e, uso de um conjugado anticorpo-fármaco |
IT202000015754A1 (it) | 2020-06-30 | 2021-12-30 | Fond Toscana Life Sciences | Antibodies to coronavirus |
EP4175982A1 (en) | 2020-06-30 | 2023-05-10 | Fondazione Toscana Life Sciences | Neutralizing antibodies to sars coronavirus-2 |
WO2022031804A1 (en) | 2020-08-04 | 2022-02-10 | Abbott Laboratories | Improved methods and kits for detecting sars-cov-2 protein in a sample |
EP4214235A1 (en) | 2020-09-16 | 2023-07-26 | LinXis B.V. | Internalizing binding molecules |
TWI815194B (zh) | 2020-10-22 | 2023-09-11 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
IL302836A (en) | 2020-11-17 | 2023-07-01 | Seagen Inc | Methods for treating cancer with a combination of tocatinib and an anti-PD-1/anti-PD-L1 antibody |
US20220241411A1 (en) | 2020-11-30 | 2022-08-04 | Incyte Corporation | Combination therapy with an anti-cd19 antibody and parsaclisib |
WO2022115120A1 (en) | 2020-11-30 | 2022-06-02 | Incyte Corporation | Combination therapy with an anti-cd19 antibody and parsaclisib |
US20220170948A1 (en) | 2020-12-01 | 2022-06-02 | Abbott Laboratories | Use of one or more biomarkers to determine traumatic brain injury (tbi) in a human subject having received a head computerized tomography scan that is negative for a tbi |
WO2023102384A1 (en) | 2021-11-30 | 2023-06-08 | Abbott Laboratories | Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi |
CA3207066A1 (en) | 2020-12-29 | 2022-07-07 | Incyte Corporation | Combination therapy comprising a2a/a2b inhibitors, pd-1/pd-l1 inhibitors, and anti-cd73 antibodies |
WO2022147147A1 (en) | 2020-12-30 | 2022-07-07 | Abbott Laboratories | Methods for determining sars-cov-2 antigen and anti-sars-cov-2 antibody in a sample |
WO2022153194A1 (en) | 2021-01-13 | 2022-07-21 | Memorial Sloan Kettering Cancer Center | Antibody-pyrrolobenzodiazepine derivative conjugate |
TW202245844A (zh) | 2021-01-13 | 2022-12-01 | 紀念斯隆凱特琳癌症中心 | 抗dll3抗體-藥物結合物 |
KR20230135586A (ko) | 2021-01-24 | 2023-09-25 | 마이클 데이비드 포레스트 | Atp 합성효소 억제제 - 미용 및 치료 용도 |
BR112023018400A2 (pt) | 2021-03-12 | 2023-12-12 | Janssen Biotech Inc | Método para tratamento de pacientes de artrite psoriática com resposta inadequada à terapia de tnf com anticorpo específico anti-il23 |
AU2022233792A1 (en) | 2021-03-12 | 2023-10-26 | Janssen Biotech, Inc. | Safe and effective method of treating psoriatic arthritis with anti-il23 specific antibody |
GB202105110D0 (en) | 2021-04-09 | 2021-05-26 | Cancer Research Tech Ltd | Anti-CD73 antibodies |
BR112023024169A2 (pt) | 2021-05-18 | 2024-02-06 | Abbott Lab | Métodos para avaliar lesão cerebral em um indivíduo pediátrico |
WO2022245671A1 (en) | 2021-05-18 | 2022-11-24 | Gilead Sciences, Inc. | Methods of using flt3l-fc fusion proteins |
EP4340875A1 (en) | 2021-05-20 | 2024-03-27 | Janssen Biotech, Inc. | Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha |
CA3220925A1 (en) | 2021-06-09 | 2022-12-15 | Kara Carter | Interferon-associated antigen binding proteins for use for the treatment or prevention of coronavirus infection |
EP4356129A1 (en) | 2021-06-14 | 2024-04-24 | Abbott Laboratories | Methods of diagnosing or aiding in diagnosis of brain injury caused by acoustic energy, electromagnetic energy, an over pressurization wave, and/or blast wind |
WO2023283345A1 (en) | 2021-07-07 | 2023-01-12 | Incyte Corporation | Anti-b7-h4 antibodies and uses thereof |
KR20240032991A (ko) | 2021-07-09 | 2024-03-12 | 얀센 바이오테크 인코포레이티드 | 항-tnf 항체 조성물의 생성을 위한 제조 방법 |
KR20240034218A (ko) | 2021-07-09 | 2024-03-13 | 얀센 바이오테크 인코포레이티드 | 항-tnf 항체 조성물을 생산하기 위한 제조 방법 |
CN117916260A (zh) | 2021-07-09 | 2024-04-19 | 詹森生物科技公司 | 用于制备抗il12/il23抗体组合物的制造方法 |
AU2022310688A1 (en) | 2021-07-13 | 2024-01-18 | Keystone Bio, Inc. | Diagnostics for porphyromonas gingivalis |
WO2023028455A1 (en) | 2021-08-23 | 2023-03-02 | Bioverativ Therapeutics Inc. | Closed-end dna production with inverted terminal repeat sequences |
IL310997A (en) | 2021-08-23 | 2024-04-01 | Bioverativ Therapeutics Inc | Factor VIII gene optimization |
WO2023028186A1 (en) | 2021-08-27 | 2023-03-02 | Abbott Laboratories | Methods for detecting immunoglobulin g, subclass 4 (igg4) in a biological sample |
WO2023034777A1 (en) | 2021-08-31 | 2023-03-09 | Abbott Laboratories | Methods and systems of diagnosing brain injury |
CA3232176A1 (en) | 2021-09-30 | 2023-04-06 | Beth MCQUISTON | Methods and systems of diagnosing brain injury |
IL311725A (en) | 2021-09-30 | 2024-05-01 | Bioverativ Therapeutics Inc | Nucleic acids encoding factor VIII polypeptides with reduced immunogenicity |
CA3236735A1 (en) | 2021-10-29 | 2023-05-04 | Seagen Inc. | Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-cd30 antibody-drug conjugate |
CA3236779A1 (en) | 2021-10-29 | 2023-05-04 | Janssen Biotech, Inc. | Methods of treating crohn's disease with anti-il23 specific antibody |
WO2023084488A1 (en) | 2021-11-15 | 2023-05-19 | Janssen Biotech, Inc. | Methods of treating crohn's disease with anti-il23 specific antibody |
WO2023094980A1 (en) | 2021-11-23 | 2023-06-01 | Fondazione Toscana Life Sciences | Antibodies to coronavirus |
US20230159633A1 (en) | 2021-11-23 | 2023-05-25 | Janssen Biotech, Inc. | Method of Treating Ulcerative Colitis with Anti-IL23 Specific Antibody |
US20230272055A1 (en) | 2021-12-08 | 2023-08-31 | Incyte Corporation | Anti-mutant calreticulin (calr) antibodies and uses thereof |
WO2023114978A1 (en) | 2021-12-17 | 2023-06-22 | Abbott Laboratories | Systems and methods for determining uch-l1, gfap, and other biomarkers in blood samples |
CA3223956A1 (en) | 2021-12-20 | 2023-06-29 | Vetoquinol Sa | Anti-canine interleukine-31-receptor a (il-31ra) antibodies and the uses thereof |
US20230357392A1 (en) | 2021-12-22 | 2023-11-09 | Morphosys Ag | Treatment Paradigm for an Anti-CD19 Antibody Therapy |
US20230213536A1 (en) | 2021-12-28 | 2023-07-06 | Abbott Laboratories | Use of biomarkers to determine sub-acute traumatic brain injury (tbi) in a subject having received a head computerized tomography (ct) scan that is negative for a tbi or no head ct scan |
TW202337904A (zh) | 2022-01-07 | 2023-10-01 | 美商壯生和壯生企業創新公司 | IL-1β結合蛋白之材料及方法 |
WO2023150652A1 (en) | 2022-02-04 | 2023-08-10 | Abbott Laboratories | Lateral flow methods, assays, and devices for detecting the presence or measuring the amount of ubiquitin carboxy-terminal hydrolase l1 and/or glial fibrillary acidic protein in a sample |
US20230312703A1 (en) | 2022-03-30 | 2023-10-05 | Janssen Biotech, Inc. | Method of Treating Psoriasis with IL-23 Specific Antibody |
WO2023213960A1 (en) | 2022-05-06 | 2023-11-09 | Genmab A/S | Methods of treating cancer with anti-tissue factor antibody-drug conjugates |
WO2023223265A1 (en) | 2022-05-18 | 2023-11-23 | Janssen Biotech, Inc. | Method for evaluating and treating psoriatic arthritis with il23 antibody |
WO2024006876A1 (en) | 2022-06-29 | 2024-01-04 | Abbott Laboratories | Magnetic point-of-care systems and assays for determining gfap in biological samples |
WO2024028732A1 (en) | 2022-08-05 | 2024-02-08 | Janssen Biotech, Inc. | Cd98 binding constructs for treating brain tumors |
WO2024028731A1 (en) | 2022-08-05 | 2024-02-08 | Janssen Biotech, Inc. | Transferrin receptor binding proteins for treating brain tumors |
WO2024036265A2 (en) | 2022-08-12 | 2024-02-15 | Takeda Vaccines, Inc. | Novel anti-denv3 antibodies |
WO2024059708A1 (en) | 2022-09-15 | 2024-03-21 | Abbott Laboratories | Biomarkers and methods for differentiating between mild and supermild traumatic brain injury |
WO2024059692A1 (en) | 2022-09-15 | 2024-03-21 | Abbott Laboratories | Hbv diagnostic, prognostic, and therapeutic methods and products |
WO2024072893A1 (en) | 2022-09-28 | 2024-04-04 | Incyte Corporation | Anti-pd-1/lag-3 bispecific antibodies and uses thereof |
WO2024097725A1 (en) | 2022-11-02 | 2024-05-10 | Takeda Vaccines, Inc. | A method for determining the infectivity of a virus |
WO2024097328A1 (en) | 2022-11-03 | 2024-05-10 | Incyte Corporation | Combination therapies comprising an anti-gitr antibody for treating cancers |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8308235D0 (en) * | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
GB8615942D0 (en) * | 1986-06-30 | 1986-08-06 | Animal & Food Research Council | Peptide production |
US5322775A (en) * | 1986-06-30 | 1994-06-21 | Pharmaceutical Proteins Ltd. | Peptide production |
EP0279582A3 (en) * | 1987-02-17 | 1989-10-18 | Pharming B.V. | Dna sequences to target proteins to the mammary gland for efficient secretion |
US4873316A (en) * | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
GB8823869D0 (en) * | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
RU2095414C1 (ru) * | 1989-12-01 | 1997-11-10 | Джен Фарминг Ойроп БВ | Трансген для получения рекомбинантного полипептида в молоке трансгенных коров, способ получения трансгенной коровы (варианты), молоко от трансгенной коровы, пищевой состав |
DE4000939A1 (de) * | 1990-01-15 | 1991-07-18 | Brem Gottfried Prof Dr Dr | Verfahren zur antikoerpergewinnung |
WO1993012227A1 (en) * | 1991-12-17 | 1993-06-24 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
EP0814159B1 (en) * | 1990-08-29 | 2005-07-27 | GenPharm International, Inc. | Transgenic mice capable of producing heterologous antibodies |
EP0710283A4 (en) * | 1993-07-22 | 1997-07-02 | Merck & Co Inc | THE EXPRESSION OF HUMAN INTERLEUKIN-1-g (b) IN A TRANSGENIC ANIMAL |
-
1993
- 1993-12-20 US US08/170,579 patent/US5827690A/en not_active Expired - Lifetime
-
1994
- 1994-12-20 DE DE69433325T patent/DE69433325T2/de not_active Expired - Lifetime
- 1994-12-20 EP EP95906691A patent/EP0741515B1/en not_active Expired - Lifetime
- 1994-12-20 WO PCT/US1994/014795 patent/WO1995017085A1/en active IP Right Grant
- 1994-12-20 NZ NZ278744A patent/NZ278744A/en not_active IP Right Cessation
- 1994-12-20 PT PT95906691T patent/PT741515E/pt unknown
- 1994-12-20 AU AU15172/95A patent/AU688845B2/en not_active Ceased
- 1994-12-20 JP JP51760295A patent/JP3970923B2/ja not_active Expired - Lifetime
- 1994-12-20 DK DK95906691T patent/DK0741515T3/da active
- 1994-12-20 ES ES95906691T patent/ES2210281T3/es not_active Expired - Lifetime
- 1994-12-20 AT AT95906691T patent/ATE253817T1/de not_active IP Right Cessation
- 1994-12-20 EP EP03077751A patent/EP1400171A1/en not_active Withdrawn
- 1994-12-20 CA CA2178941A patent/CA2178941C/en not_active Expired - Lifetime
-
1995
- 1995-03-27 US US08/410,887 patent/US5849992A/en not_active Expired - Lifetime
-
1998
- 1998-01-23 US US09/012,904 patent/US20040006776A1/en not_active Abandoned
- 1998-06-19 AU AU73079/98A patent/AU7307998A/en not_active Abandoned
-
2006
- 2006-10-04 JP JP2006273219A patent/JP2007006900A/ja active Pending
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009512694A (ja) * | 2005-10-21 | 2009-03-26 | ジーティーシー バイオセラピューティックス インコーポレイテッド | 抗体依存性細胞障害活性を増強させた抗体、その調製法および使用法 |
JP2012250984A (ja) * | 2005-10-21 | 2012-12-20 | Gtc Biotherapeutics Inc | 抗体依存性細胞障害活性を増強させた抗体、その調製法および使用法 |
JP2014525395A (ja) * | 2011-08-10 | 2014-09-29 | ラボラトワール フランセ デュ フラクショヌマン エ デ ビオテクノロジー | 高度ガラクトシル化抗体 |
US10034921B2 (en) | 2013-02-13 | 2018-07-31 | Laboratoire Français Du Fractionnement Et Des Biotechnologies | Proteins with modified glycosylation and methods of production thereof |
US10174110B2 (en) | 2013-02-13 | 2019-01-08 | Laboratoire Français Du Fractionnement Et Des Biotechnologies | Highly galactosylated anti-TNF-α antibodies and uses thereof |
JP2017520531A (ja) * | 2014-06-02 | 2017-07-27 | ラボラトワール フランセ デュ フラクショヌマン エ デ ビオテクノロジーLaboratoire Francais du Fractionnement et des Biotechnologies | Fc断片の産生 |
Also Published As
Publication number | Publication date |
---|---|
CA2178941A1 (en) | 1995-06-29 |
DE69433325T2 (de) | 2004-09-16 |
EP0741515B1 (en) | 2003-11-12 |
NZ278744A (en) | 1997-04-24 |
EP0741515A4 (en) | 1998-05-27 |
JP2007006900A (ja) | 2007-01-18 |
US5827690A (en) | 1998-10-27 |
EP0741515A1 (en) | 1996-11-13 |
WO1995017085A1 (en) | 1995-06-29 |
DK0741515T3 (da) | 2004-03-08 |
EP1400171A1 (en) | 2004-03-24 |
AU688845B2 (en) | 1998-03-19 |
PT741515E (pt) | 2004-03-31 |
ATE253817T1 (de) | 2003-11-15 |
JP3970923B2 (ja) | 2007-09-05 |
AU7307998A (en) | 1998-08-20 |
DE69433325D1 (de) | 2003-12-18 |
ES2210281T3 (es) | 2004-07-01 |
US20040006776A1 (en) | 2004-01-08 |
AU1517295A (en) | 1995-07-10 |
CA2178941C (en) | 2010-10-26 |
US5849992A (en) | 1998-12-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3970923B2 (ja) | 乳汁中における抗体の形質転換的な産生 | |
Meade et al. | Bovine alphas1-casein gene sequences direct high level expression of active human urokinase in mouse milk | |
Shani et al. | Expression of human serum albumin in the milk of transgenic mice | |
Ebert et al. | Transgenic farm animals: progress report | |
EP1739170A2 (en) | Transgenic animals expressing human coagulation factor VIII and von Willebrand factor | |
US7435869B2 (en) | Transgenic nonhuman mammals producing fibrinogen in milk and methods of producing fibrin | |
JP2014121337A (ja) | トランスジェニック哺乳動物の乳汁に産生されるc1インヒビター | |
JP2006507839A (ja) | 乳中に安定して産生される改変抗体およびその製造方法 | |
JPH09509839A (ja) | トランスジェニック動物内でのフィブリノーゲンの製造 | |
US8173860B2 (en) | Non-human transgenic mammal expressing a human FcRn on its mammary gland cells and expressing a transgenic protein-human Fc-domain fusion | |
JPH11262396A (ja) | 異種抗体の生成 | |
US5670134A (en) | Method for evaluating and modifying biological activity | |
JP2003521914A (ja) | トランスジェニック哺乳動物の乳汁に産生されるc1インヒビター | |
US20120259093A1 (en) | Expression of secreted human alpha-fetoprotein in transgenic animals | |
US20020062492A1 (en) | Transgenic animals expressing human coagulation factor VIII and von willebrand factor | |
Gutiérrez et al. | Expression of a bovine κ-CN cDNA in the mammary gland of transgenic mice utilizing a genomic milk protein gene as an expression cassette | |
AU2002315884B2 (en) | Process for constructing mutant | |
JP2004500890A (ja) | 遺伝子導入によって作成された血小板由来増殖因子 | |
AU2003248473B2 (en) | Transgenic production of antibodies in milk | |
WO1995017200A1 (en) | METHODS FOR THE PRODUCTION AND USE OF ANTI-IDIOTYPIC ANTIBODIES USING HUMAN Ig EXPRESSING TRANSGENIC ANIMALS | |
AU2007205719A1 (en) | Transgenic production of antibodies in milk | |
DEYKIN et al. | RESEARCH RESULTS IN PHARMACOLOGY | |
WO2020053661A1 (en) | Methods of purifying antibodies from the milk of transgenic non-human mammals comprising the use of chitosan | |
Velander | Transgenic mammals expressing human coagulation factor VIII | |
CA2309891A1 (en) | Production of fibrinogen in transgenic animals |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A72 | Notification of change in name of applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A721 Effective date: 20040129 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20040817 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20041117 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20050107 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050217 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20060606 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20061004 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20061207 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070116 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070410 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20070508 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20070607 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110615 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120615 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120615 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130615 Year of fee payment: 6 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
EXPY | Cancellation because of completion of term |